

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

#483

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/16		(11) International Publication Number: WO 98/30231
A1		(43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US98/00449		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 7 January 1998 (07.01.98)		
(30) Priority Data: 60/034,905 7 January 1997 (07.01.97) US 60/055,404 8 August 1997 (08.08.97) US 60/066,029 14 November 1997 (14.11.97) US 60/065,442 14 November 1997 (14.11.97) US		
(71) Applicant: AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Centre Drive, San Diego, CA 92121 (US).		
(72) Inventors: BEELEY, Nigel, Robert, Arnold; 227 Loma Corta Drive, Solana Beach, CA 92075 (US). PRICKETT, Kathryn, S.; 7612 Trailbrush Terrace, San Diego, CA 92126 (US). BHAVSAR, Sunil; Apartment #7, 917 Torrance Street, San Diego, CA 92103 (US).		
(74) Agents: DUFT, Bradford, J. et al.; Lyon & Lyon LLP, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).		

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.***(54) Title:** USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE**(57) Abstract**

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that effect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF EXENDINS AND AGONISTS THEREOF
FOR THE REDUCTION OF FOOD INTAKE

This application claims the benefit of U.S. Provisional Application No. 60/034,905, filed January 7, 1997, U.S. Provisional Application No. 60/055,404, filed August 8, 1997, U.S. Provisional Application No. 60/066,029
5 filed November 14, 1997, and U.S. Provisional Application No. 60/065,442, November 14, 1997.

FIELD OF THE INVENTION

10 The present invention relates to methods for treating conditions or disorders which can be alleviated by reducing food intake comprising administration of an effective amount of an exendin or an exendin agonist alone or in
15 conjunction with other compounds or compositions that affect satiety such as a leptin or an amylin agonist. The methods are useful for treating conditions or disorders, in which the reduction of food intake is of value, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for
20 lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the

invention are also disclosed.

BACKGROUND

The following description summarizes information relevant to the present invention. It is not an admission that any of the information provided herein is prior art to the presently claimed invention, nor that any of the publications specifically or implicitly referenced are prior art to that invention.

Exendin

Exendins are peptides that are found in the venom of the Gila-monster, a lizard found in Arizona, and the Mexican Beaded Lizard. Exendin-3 is present in the venom of Heloderma horridum, and exendin-4 is present in the venom of Heloderma suspectum (Eng, J., et al., J. Biol. Chem., 265:20259-62, 1990; Eng., J., et al., J. Biol. Chem., 267:7402-05, 1992). The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36]NH₂ (Goke, et al., J. Biol. Chem., 268:19650-55, 1993). GLP-1[7-36]NH₂, also known as proglucagon[78-107], has an insulinitropic effect, stimulating insulin secretion from pancreatic β -cells; GLP also inhibits glucagon secretion from pancreatic α -cells (Orskov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al., J. Clin. Invest., 97:133-38,

1996). GLP-1 is reported to inhibit gastric emptying (Williams B, et al., J Clin Endocrinol Metab 81 (1): 327-32, 1996; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993), and gastric acid secretion. (Schjoldager BT, et al., Dig Dis Sci 34 (5): 703-8, 1989; O'Halloran DJ, et al., J Endocrinol 126 (1): 169-73, 1990; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993). GLP-1[7-37], which has an additional glycine residue at its carboxy terminus, also stimulates insulin secretion in humans (Orskov, et al., Diabetes, 42:658-61, 1993). A transmembrane G-protein adenylate-cyclase-coupled receptor believed to be responsible for the insulinotropic effect of GLP-1 is reported to have been cloned from a β -cell line (Thorens, Proc. Natl. Acad. Sci. USA 89:8641-45 (1992)).

15 Exendin-4 potently binds at GLP-1 receptors on insulin-secreting β TC1 cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also said to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Goke, et al., J. Biol. Chem. 268:19650-55, 1993; Schepp, et al., Eur. J. Pharmacol., 69:183-91, 1994; Eissele, et al., Life Sci., 55:629-34, 1994). Exendin-3 and exendin-4 were reported to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra, R., et al., Regulatory Peptides, 41:149-56, 1992; Raufman, et al.,

J. Biol. Chem. 267:21432-37, 1992; Singh, et al., Regul. Pept. 53:47-59, 1994). The use of exendin-3 and exendin-4 as insulinotrophic agents for the treatment of diabetes mellitus and the prevention of hyperglycemia has been
5 proposed (Eng, U.S. Patent No. 5,424,286).

C-terminally truncated exendin peptides such as exendin[9-39], a carboxyamidated molecule, and fragments 3-39 through 9-39 have been reported to be potent and selective antagonists of GLP-1 (Goke, et al., J. Biol. Chem., 268:19650-55, 1993; Raufman, J.P., et al., J. Biol. Chem. 266:2897-902, 1991; Schepp, W., et al., Eur. J. Pharm. 269:183-91, 1994; Montrose-Rafizadeh, et al., Diabetes, 45(Suppl. 2):152A, 1996). Exendin[9-39] is said to block endogenous GLP-1 in vivo, resulting in reduced
10 insulin secretion. Wang, et al., J. Clin. Invest., 95:417-21, 1995; D'Alessio, et al., J. Clin. Invest., 97:133-38, 1996). The receptor apparently responsible for the insulinotropic effect of GLP-1 has reportedly been cloned from rat pancreatic islet cell (Thorens, B., Proc. Natl. Acad. Sci. USA 89:8641-8645, 1992).
15 Exendins and exendin[9-39] are said to bind to the cloned GLP-1 receptor (rat pancreatic β -cell GLP-1 receptor (Fehmann HC, et al., Peptides 15 (3): 453-6, 1994) and human GLP-1 receptor (Thorens B, et al., Diabetes 42 (11): 1678-82, 1993). In
20 cells transfected with the cloned GLP-1 receptor, exendin-4
25

is reportedly an agonist, i.e., it increases cAMP, while exendin[9-39] is identified as an antagonist, i.e., it blocks the stimulatory actions of exendin-4 and GLP-1. Id.

Exendin[9-39] is also reported to act as an antagonist
5 of the full length exendins, inhibiting stimulation of pancreatic acinar cells by exendin-3 and exendin-4 (Raufman, et al., J. Biol. Chem. 266:2897-902, 1991; Raufman, et al., J. Biol. Chem., 266:21432-37, 1992). It is also reported that exendin[9-39] inhibits the
10 stimulation of plasma insulin levels by exendin-4, and inhibits the somatostatin release-stimulating and gastrin release-inhibiting activities of exendin-4 and GLP-1 (Kolligs, F., et al., Diabetes, 44:16-19, 1995; Eissele, et al., Life Sciences, 55:629-34, 1994).

15 Exendins have recently been found to inhibit gastric emptying (U.S.S.N. 08/694,954, filed August 8, 1996, which enjoys common ownership with the present invention and is hereby incorporated by reference).

Exendin [9-39] has been used to investigate the
20 physiological relevance of central GLP-1 in control of food intake (Turton, M.D. et al. Nature 379:69-72, 1996). GLP-1 administered by intracerebroventricular injection inhibits food intake in rats. This satiety-inducing effect of GLP-1 delivered ICV is reported to be inhibited by ICV injection
25 of exendin [9-39] (Turton, supra). However, it has been

reported that GLP-1 does not inhibit food intake in mice when administered by peripheral injection (Turton, M.D., Nature 379:69-72, 1996; Bhavsar, S.P., Soc. Neurosci. Abstr. 21:460 (188.8), 1995).

5

Obesity and Hypernutrition

Obesity, excess adipose tissue, is becoming increasingly prevalent in developed societies. For example, approximately 30% of adults in the U.S. were estimated to be 20 percent above desirable body weight --
10 an accepted measure of obesity sufficient to impact a health risk (*Harrison's Principles of Internal Medicine* 12th Edition, McGraw Hill, Inc. (1991) p. 411). The pathogenesis of obesity is believed to be multifactorial but the basic problem is that in obese subjects food intake
15 and energy expenditure do not come into balance until there is excess adipose tissue. Attempts to reduce food intake, or hypernutrition, are usually fruitless in the medium term because the weight loss induced by dieting results in both increased appetite and decreased energy expenditure (Leibel
20 et al., (1995) *New England Journal of Medicine* 322: 621-628). The intensity of physical exercise required to expend enough energy to materially lose adipose mass is too great for most people to undertake on a sufficiently frequent basis. Thus, obesity is currently a poorly
25 treatable, chronic, essentially intractable metabolic

disorder. Not only is obesity itself believed by some to be undesirable for cosmetic reasons, but obesity also carries serious risk of co-morbidities including, Type 2 diabetes, increased cardiac risk, hypertension, atherosclerosis, degenerative arthritis, and increased incidence of complications of surgery involving general anesthesia. Obesity due to hypernutrition is also a risk factor for the group of conditions called insulin resistance syndrome, or "syndrome X." In syndrome X, it has been reported that there is a linkage between insulin resistance and hypertension. (Watson N. and Sandler M., *Curr. Med. Res. Opin.*, 12(6):374-378 (1991); Kodama J. et al., *Diabetes Care*, 13(11):1109-1111 (1990); Lithell et al., *J. Cardiovasc. Pharmacol.*, 15 Suppl. 5:S46-S52 (1990)).

In those few subjects who do succeed in losing weight, by about 10 percent of body weight, there can be striking improvements in co-morbid conditions, most especially Type 2 diabetes in which dieting and weight loss are the primary therapeutic modality, albeit relatively ineffective in many patients for the reasons stated above. Reducing food intake in obese subjects would decrease the plasma glucose level, the plasma lipid level, and the cardiac risk in these subjects. Hypernutrition is also the result of, and the psychological cause of, many eating disorders.

Reducing food intake would also be beneficial in the treatment of such disorders.

Thus, it can be appreciated that an effective means to reduce food intake is a major challenge and a superior method of treatment would be of great utility. Such a method, and compounds and compositions which are useful therefor, have been invented and are described and claimed herein.

10

SUMMARY OF THE INVENTION

The present invention concerns the surprising discovery that exendins and exendin agonists have a profound and prolonged effect on inhibiting food intake.

15 The present invention is directed to novel methods for treating conditions or disorders associated with hypernutrition, comprising the administration of an exendin, for example, exendin-3 [SEQ ID NO. 1: His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg
20 Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or exendin-4 [SEQ ID NO. 2: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or other compounds which
25 effectively bind to the receptor at which exendin exerts its

action on reducing food intake. These methods will be useful in the treatment of, for example, obesity, diabetes, including Type II or non-insulin dependent diabetes, eating disorders, and insulin-resistance syndrome.

5 In a first aspect, the invention features a method of treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to the subject a therapeutically effective amount of an exendin or an exendin agonist. By an "exendin agonist" is
10 meant a compound that mimics the effects of exendin on the reduction of food intake by binding to the receptor or receptors where exendin causes this effect. Preferred exendin agonist compounds include those described in United States Provisional Patent Application Serial No. 60/055,404,
15 entitled, "Novel Exendin Agonist Compounds," filed August 8, 1997; United States Provisional Patent Application Serial No. 60/065,442, entitled, "Novel Exendin Agonist Compounds," filed November 14, 1997; and United States Provisional Patent Application Serial No. 60/066,029, entitled, "Novel
20 Exendin Agonist Compounds," filed November 14, 1997; all of which enjoy common ownership with the present application and all of which are incorporated by this reference into the present application as though fully set forth herein. By "condition or disorder which can be alleviated by reducing
25 food intake" is meant any condition or disorder in a subject

that is either caused by, complicated by, or aggravated by a relatively high food intake, or that can be alleviated by reducing food intake. Such conditions or disorders include, but are not limited to, obesity, diabetes, including Type II
5 diabetes, eating disorders, and insulin-resistance syndrome.

Thus, in a first embodiment, the present invention provides a method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically
10 effective amount of an exendin or an exendin agonist. Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Serial Nos. 60/055,404; 60/065,442; and 60/066,029, which have been incorporated by reference in the present application.

15 Preferably, the subject is a vertebrate, more preferably a mammal, and most preferably a human. In preferred aspects, the exendin or exendin agonist is administered parenterally, more preferably by injection. In a most preferred aspect, the injection is a peripheral injection. Preferably, about
20 10 μ g-30 μ g to about 5 mg of the exendin or exendin agonist is administered per day. More preferably, about 10-30 μ g to about 2mg, or about 10-30 μ g to about 1mg of the exendin or exendin agonist is administered per day. Most preferably, about 30 μ g to about 500 μ g of the exendin or exendin
25 agonist is administered per day.

In various preferred embodiments of the invention, the condition or disorder is obesity, diabetes, preferably Type II diabetes, an eating disorder, or insulin-resistance syndrome.

5 In other preferred aspects of the invention, a method is provided for reducing the appetite of a subject comprising administering to said subject an appetite-lowering amount of an exendin or an exendin agonist.

10 In yet other preferred aspects, a method is provided for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

The methods of the present invention may also be used to reduce the cardiac risk of a subject comprising
15 administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. In one preferred aspect, the exendin or exendin agonist used in the methods of the present invention is exendin-3. In another preferred aspect, said exendin is exendin-4. Other
20 preferred exendin agonists include exendin-4 (1-30) [SEQ ID NO 6: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly], exendin-4 (1-30) amide [SEQ ID NO 7: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala
25 Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH₂],

exendin-4 (1-28) amide [SEQ ID NO 40: His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn-NH₂], ¹⁴Leu, ²⁵Phe exendin-4
amide [SEQ ID NO 9: His Gly Glu Gly Thr Phe Thr Ser Asp Leu
5 Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH₂],
¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide [SEQ ID NO 41: His Gly Glu
Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala
Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂], and
10 ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide [SEQ ID NO 8: His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu
Ala Val Arg Leu Ala Ile Glu Phe Leu Lys Asn-NH₂].

In the methods of the present invention, the exendins
and exendin agonists may be administered separately or
15 together with one or more other compounds and compositions
that exhibit a long term or short-term satiety action,
including, but not limited to other compounds and
compositions that comprise an amylin agonist,
cholecystokinin (CCK), or a leptin (ob protein). Suitable
20 amylin agonists include, for example, [^{25,28,29}Pro-]-human
amylin (also known as "pramlintide," and previously referred
to as "AC-137") as described in "Amylin Agonist Peptides and
Uses Therefor," U.S. Patent No. 5,686,511, issued November
11, 1997, and salmon calcitonin. The CCK used is preferably
25 CCK octopeptide (CCK-8). Leptin is discussed in, for

example, Pelleymounter, M.A., et al. Science 269:540-43 (1995); Halaas, J.L., et al. Science 269:543-46 (1995); and Campfield, L.A., et al. Eur. J. Pharmac. 262:133-41 (1994).

5 In other embodiments of the invention is provided a pharmaceutical composition for use in the treatment of conditions or disorders which can be alleviated by reducing food intake comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier. Preferably, the
10 pharmaceutical composition comprises a therapeutically effective amount for a human subject.

The pharmaceutical composition may preferably be used for reducing the appetite of a subject, reducing the weight of a subject, lowering the plasma lipid level of a subject,
15 or reducing the cardiac risk of a subject. Those of skill in the art will recognize that the pharmaceutical composition will preferably comprise a therapeutically effective amount of an exendin or exendin agonist to accomplish the desired effect in the subject.

20 The pharmaceutical compositions may further comprise one or more other compounds and compositions that exhibit a long-term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, CCK, preferably CCK-8, or leptin. Suitable
25 amylin agonists include, for example, [^{25,28,29}Pro]-human amylin.

and salmon calcitonin.

In one preferred aspect, the pharmaceutical composition comprises exendin-3. In another preferred aspect, the pharmaceutical composition comprises exendin-4. In other preferred aspects, the pharmaceutical compositions comprises a peptide selected from: exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu, ²⁵Phe exendin-4 amide, ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 and GLP-1.

15

Figure 2 is a graphical depiction of the change of food intake in obese mice after intraperitoneal injection of exendin-4.

Figure 3 is a graphical depiction of the change of food intake in rats after intracerebroventricular injection of exendin-4

20

Figure 4 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) ("Compound 1").

Figure 5 is a graphical depiction of the change of food

25

intake in normal mice after intraperitoneal injection of
exendin-4 (1-30) amide ("Compound 2").

Figure 6 is a graphical depiction of the change of food
intake in normal mice after intraperitoneal injection of
5 exendin-4 (1-28) amide ("Compound 3").

Figure 7 is a graphical depiction of the change of food
intake in normal mice after intraperitoneal injection of
¹⁴Leu, ²⁵Phe exendin-4 amide ("Compound 4").

Figure 8 is a graphical depiction of the change of food
10 intake in normal mice after intraperitoneal injection of
¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide ("Compound 5").

Figure 9 is a graphical depiction of the change of food
intake in normal mice after intraperitoneal injection of
¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide ("Compound 6").

15 Figure 10 depicts the amino acid sequences for certain
exendin agonist compounds useful in the present invention
[SEQ ID NOS 9-39].

DETAILED DESCRIPTION OF THE INVENTION

20 Exendins and exendin agonists are useful as described
herein in view of their pharmacological properties.
Activity as exendin agonists can be indicated by activity in
the assays described below. Effects of exendins or exendin
agonists on reducing food intake can be identified,
25 evaluated, or screened for, using the methods described in


the Examples below, or other methods known in the art for determining effects on food intake or appetite.

Exendin Agonist Compounds

5

Exendin agonist compounds are those described in U.S. Provisional Application No. 60/055,404, including compounds of the formula (I) [SEQ ID NO. 3]:

10



20

wherein Xaa₁ is His, Arg or Tyr; Xaa₂ is Ser, Gly, Ala or Thr; Xaa₃ is Asp or Glu; Xaa₄ is Phe, Tyr or naphthylalanine; Xaa₅ is Thr or Ser; Xaa₆ is Ser or Thr; Xaa₇ is Asp or Glu; Xaa₈ is Leu, Ile, Val, pentylglycine or Met; Xaa₉ is Leu, Ile, pentylglycine, Val or Met; Xaa₁₀ is Phe, Tyr or naphthylalanine; Xaa₁₁ is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa₁₂ is Glu or Asp; Xaa₁₃ is Trp, Phe, Tyr, or naphthylalanine; Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa₁₈ is Ser, Thr or Tyr; and Z is -OH or -NH₂; with the proviso that the compound is not exendin-3 or

30

exindin-4.

Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds include those listed in Figure 10 having amino acid sequences of SEQ. ID. NOS. 9 to 39.

Preferred exendin agonist compounds include those wherein Xaa₁ is His or Tyr. More preferably Xaa₁ is His.

Preferred are those compounds wherein Xaa₂ is Gly.

Preferred are those compounds wherein Xaa₃ is Leu, pentylglycine or Met.

Preferred compounds include those wherein Xaa₁₃ is Trp or Phe.

Also preferred are compounds where Xaa₄ is Phe or naphthylalanine; Xaa₁₁ is Ile or Val and Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are independently selected from Pro, homoproline, thioproline or N-alkylalanine. Preferably N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.

According to an especially preferred aspect, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are the same amino acid residue.

Preferred are compounds wherein Xaa₁₈ is Ser or Tyr, more preferably Ser.

Preferably Z is -NH₂.

According to one aspect, preferred are compounds of

formula (I) wherein Xaa₁ is His or Tyr, more preferably His; Xaa₂ is Gly; Xaa₄ is Phe or naphthylalanine; Xaa₉ is Leu, pentylglycine or Met; Xaa₁₀ is Phe or naphthylalanine; Xaa₁₁ is Ile or Val; Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are independently
5 selected from Pro, homoproline, thioproline or N-alkylalanine; and Xaa₁₈ is Ser or Tyr, more preferably Ser. More preferably Z is -NH₂.

According to an especially preferred aspect, especially preferred compounds include those of formula (I)
10 wherein: Xaa₁ is His or Arg; Xaa₂ is Gly; Xaa₃ is Asp or Glu; Xaa₄ is Phe or naphthylalanine; Xaa₅ is Thr or Ser; Xaa₆ is Ser or Thr; Xaa₇ is Asp or Glu; Xaa₈ is Leu or pentylglycine; Xaa₉ is Leu or pentylglycine; Xaa₁₀ is Phe or naphthylalanine; Xaa₁₁ is Ile, Val or t-butyltylglycine;
15 Xaa₁₂ is Glu or Asp; Xaa₁₃ is Trp or Phe; Xaa₁₄, Xaa₁₅, Xaa₁₆, and Xaa₁₇ are independently Pro, homoproline, thioproline, or N-methylalanine; Xaa₁₈ is Ser or Tyr; and Z is -OH or -NH₂; with the proviso that the compound does not have the formula of either SEQ. ID. NOS. 1 or 2. More preferably Z
20 is -NH₂. Especially preferred compounds include those having the amino acid sequence of SEQ. ID. NOS. 9, 10, 21, 22, 23, 26, 28, 34, 35 and 39.

According to an especially preferred aspect, provided
25 are compounds where Xaa₉ is Leu, Ile, Val or pentylglycine,

more preferably Leu or pentylglycine, and Xaa₁₁ is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will exhibit advantageous duration of action and be less subject to oxidative degradation, both in vitro and in vivo, as well as during synthesis of the compound.

Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442, including compounds of the formula (II) [SEQ ID NO. 4]:

10

Xaa₁ Xaa₂ Xaa₃ Gly Xaa₅ Xaa₆ Xaa₇ Xaa₈ Xaa₉ Xaa₁₀
Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Ala Xaa₁₉ Xaa₂₀
Xaa₂₁ Xaa₂₂ Xaa₂₃ Xaa₂₄ Xaa₂₅ Xaa₂₆ Xaa₂₇ Xaa₂₈-Z₁; wherein

15

Xaa₁ is His, Arg or Tyr;

Xaa₂ is Ser, Gly, Ala or Thr;

Xaa₃ is Asp or Glu;

Xaa₅ is Ala or Thr;

Xaa₆ is Ala, Phe, Tyr or naphthylalanine;

20

Xaa₇ is Thr or Ser;

Xaa₈ is Ala, Ser or Thr;

Xaa₉ is Asp or Glu;

Xaa₁₀ is Ala, Leu, Ile, Val, pentylglycine or Met;

Xaa₁₁ is Ala or Ser;

25

Xaa₁₂ is Ala or Lys;

- Xaa₁₃ is Ala or Gln;
 Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;
 Xaa₁₅ is Ala or Glu;
 Xaa₁₆ is Ala or Glu;
 5 Xaa₁₇ is Ala or Glu;
 Xaa₁₉ is Ala or Val;
 Xaa₂₀ is Ala or Arg;
 Xaa₂₁ is Ala or Leu;
 Xaa₂₂ is Ala, Phe, Tyr or naphthylalanine;
 10 Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine
 or Met;
 Xaa₂₄ is Ala, Glu or Asp;
 Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine;
 Xaa₂₆ is Ala or Leu;
 15 Xaa₂₇ is Ala or Lys;
 Xaa₂₈ is Ala or Asn;
 Z₁ is-OH,
 -NH₂,
 Gly-Z₂,
 20 Gly Gly-Z₂,
 Gly Gly Xaa₃₁-Z₂,
 Gly Gly Xaa₃₁ Ser-Z₂,
 Gly Gly Xaa₃₁ Ser Ser-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly-Z₂,
 25 Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,

Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂,
Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂ or
Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂;
Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ are independently Pro,
5 homoproline, 3Hyp, 4Hyp, thioproline,
N-alkylglycine, N-alkylpentylglycine or
N-alkylalanine; and
Z₂ is -OH or -NH₂;
provided that no more than three of Xaa₃, Xaa₅, Xaa₆, Xaa₈,
10 Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Xaa₁₉,
Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈ are Ala.
Preferred N-alkyl groups for N-alkylglycine, N-
alkylpentylglycine and N-alkylalanine include lower alkyl
groups preferably of 1 to about 6 carbon atoms, more
15 preferably of 1 to 4 carbon atoms.

Preferred exendin agonist compounds include those
wherein Xaa₁ is His or Tyr. More preferably Xaa₁ is His.

Preferred are those compounds wherein Xaa₂ is Gly.

Preferred are those compounds wherein Xaa₁₄ is Leu,
20 pentylglycine or Met.

Preferred compounds are those wherein Xaa₂₅ is Trp or
Phe.

Preferred compounds are those where Xaa₆ is Phe or
naphthylalanine; Xaa₂₂ is Phe or naphthylalanine and
25 Xaa₂₃ is Ile or Val.

Preferred are compounds wherein Xaa₃₁, Xaa₃₆, Xaa₃₇, and Xaa₃₈ are independently selected from Pro, homoproline, thioproline and N-alkylalanine.

Preferably Z₁ is -NH₂.

5 Preferable Z₂ is -NH₂.

According to one aspect, preferred are compounds of formula (I) wherein Xaa₁ is His or Tyr, more preferably His; Xaa₂ is Gly; Xaa₆ is Phe or naphthylalanine; Xaa₁₄ is Leu, pentylglycine or Met; Xaa₂₂ is Phe or naphthylalanine; Xaa₂₃ is Ile or Val; Xaa₃₁, Xaa₃₆, Xaa₃₇, and Xaa₃₈ are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z₁ is -NH₂.

According to an especially preferred aspect, especially preferred compounds include those of formula (I) wherein: Xaa₁ is His or Arg; Xaa₂ is Gly or Ala; Xaa₃ is Asp or Glu; Xaa₅ is Ala or Thr; Xaa₆ is Ala, Phe or naphthylalanine; Xaa₇ is Thr or Ser; Xaa₈ is Ala, Ser or Thr; Xaa₉ is Asp or Glu; Xaa₁₀ is Ala, Leu or pentylglycine; Xaa₁₁ is Ala or Ser; Xaa₁₂ is Ala or Lys; Xaa₁₃ is Ala or Gln; Xaa₁₄ is Ala, Leu or pentylglycine; Xaa₁₅ is Ala or Glu; Xaa₁₆ is Ala or Glu; Xaa₁₇ is Ala or Glu; Xaa₁₉ is Ala or Val; Xaa₂₀ is Ala or Arg; Xaa₂₁ is Ala or Leu; Xaa₂₂ is Phe or naphthylalanine; Xaa₂₃ is Ile, Val or tert-butylglycine; Xaa₂₄ is Ala, Glu or Asp; Xaa₂₅ is Ala, Trp or Phe; Xaa₂₆ is Ala or Leu; Xaa₂₇ is Ala or Lys; Xaa₂₈ is Ala or Asn; Z₁ is -

OH, -NH₂, Gly-Z₂, Gly Gly-Z₂, Gly Gly Xaa₃₁-Z₂, Gly Gly Xaa₃₁
 Ser-Z₂, Gly Gly Xaa₃₁ Ser Ser-Z₂, Gly Gly Xaa₃₁ Ser Ser Gly-
 Z₂, Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂, Gly Gly Xaa₃₁ Ser Ser
 Gly Ala Xaa₃₆-Z₂, Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂,
 5 Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂; Xaa₃₁, Xaa₃₆,
 Xaa₃₇ and Xaa₃₈ being independently Pro homoproline,
 thioproline or N-methylalanine; and Z₂ being -OH or -NH₂;
 provided that no more than three of Xaa₃, Xaa₅, Xaa₆, Xaa₈,
 Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Xaa₁₉,
 10 Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈ are Ala.
 Especially preferred compounds include those having the
 amino acid sequence of SEQ. ID. NOS. 40-61.

According to an especially preferred aspect, provided
 are compounds where Xaa₁₄ is Leu, Ile, Val or pentylglycine,
 15 more preferably Leu or pentylglycine, and Xaa₂₅ is Phe, Tyr
 or naphthylalanine, more preferably Phe or naphthylalanine.
 These compounds will be less susceptible to oxidative
 degradation, both in vitro and in vivo, as well as during
 synthesis of the compound.

20 Exendin agonist compounds also include those described
 in U.S. Provisional Application No. 60/066,029, including
 compounds of the formula (III) [SEQ ID NO. 5]:

Xaa₁ Xaa₂ Xaa₃ Xaa₄ Xaa₅ Xaa₆ Xaa₇ Xaa₈ Xaa₉ Xaa₁₀
 25 Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Ala Xaa₁₉ Xaa₂₀

Xaa₂₁ Xaa₂₂ Xaa₂₃ Xaa₂₄ Xaa₂₅ Xaa₂₆ Xaa₂₇ Xaa₂₈-Z₁; wherein

Xaa₁ is His, Arg, Tyr, Ala, Norval, Val
or Norleu;

5 Xaa₂ is Ser, Gly, Ala or Thr;

Xaa₃ is Ala, Asp or Glu;

Xaa₄ is Ala, Norval, Val, Norleu or Gly;

Xaa₅ is Ala or Thr;

Xaa₆ is Phe, Tyr or naphthylalanine;

10 Xaa₇ is Thr or Ser;

Xaa₈ is Ala, Ser or Thr;

Xaa₉ is Ala, Norval, Val, Norleu, Asp or Glu;

Xaa₁₀ is Ala, Leu, Ile, Val, pentylglycine or Met;

Xaa₁₁ is Ala or Ser;

15 Xaa₁₂ is Ala or Lys;

Xaa₁₃ is Ala or Gln;

Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;

Xaa₁₅ is Ala or Glu;

Xaa₁₆ is Ala or Glu;

20 Xaa₁₇ is Ala or Glu;

Xaa₁₉ is Ala or Val;

Xaa₂₀ is Ala or Arg;

Xaa₂₁ is Ala or Leu;

Xaa₂₂ is Phe, Tyr or naphthylalanine;

25 Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine or

Met;

Xaa₂₄ is Ala, Glu or Asp;

Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine;

Xaa₂₆ is Ala or Leu;

5 Xaa₂₇ is Ala or Lys;

Xaa₂₈ is Ala or Asn;

Z₁ is -OH,

-NH₂,

Gly-Z₂,

10 Gly Gly-Z₂,

Gly Gly Xaa₃₁-Z₂,

Gly Gly Xaa₃₁ Ser-Z₂,

Gly Gly Xaa₃₁ Ser Ser-Z₂,

Gly Gly Xaa₃₁ Ser Ser Gly-Z₂,

15 Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,

Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂,

Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂,

Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂ or Gly

Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈ Xaa₃₉-Z₂; wherein

20 Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ are independently

Pro, homoproline, 3Hyp, 4Hyp, thioproline,

N-alkylglycine, N-alkylpentylglycine or

N-alkylalanine; and

Z₂ is -OH or -NH₂;

25 provided that no more than three of Xaa₃, Xaa₄, Xaa₅, Xaa₆,

Xaa₈, Xaa₉, Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇,
Xaa₁₉, Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈ are
Ala; and provided also that, if Xaa₁ is His, Arg or Tyr,
then at least one of Xaa₃, Xaa₄ and Xaa₅ is Ala.

5

Definitions

In accordance with the present invention and as used
herein, the following terms are defined to have the
following meanings, unless explicitly stated otherwise.


- 10 The term "amino acid" refers to natural amino acids,
unnatural amino acids, and amino acid analogs, all in their
D and L stereoisomers if their structure allow such
stereoisomeric forms. Natural amino acids include alanine
(Ala), arginine (Arg), asparagine (Asn), aspartic acid
15 (Asp), cysteine (Cys), glutamine (Gln), glutamic acid
(Glu), glycine (Gly), histidine (His), isoleucine (Ile),
leucine (Leu), Lysine (Lys), methionine (Met),
phenylalanine (Phe), proline (Pro), serine (Ser), threonine
(Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val).
20 Unnatural amino acids include, but are not limited to
azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic
acid, beta-alanine, aminopropionic acid, 2-aminobutyric
acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-
aminoheptanoic acid, 2-aminoisobutyric acid, 3-
25 aminoisbutyric acid, 2-aminopimelic acid, tertiary-

butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-
diaminopimelic acid, 2,3-diaminopropionic acid, N-
ethylglycine, N-ethylasparagine, homoproline,
hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-
5 hydroxyproline, isodesmosine, allo-isoleucine, N-
methylalanine, N-methylglycine, N-methylisoleucine, N-
methylpentylglycine, N-methylvaline, naphthalanine,
norvaline, norleucine, ornithine, pentylglycine, pipecolic
acid and thioproline. Amino acid analogs include the
10 natural and unnatural amino acids which are chemically
blocked, reversibly or irreversibly, or modified on their
N-terminal amino group or their side-chain groups, as for
example, methionine sulfoxide, methionine sulfone, S-
(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine
15 sulfoxide and S-(carboxymethyl)-cysteine sulfone.

The term "amino acid analog" refers to an amino acid
wherein either the C-terminal carboxy group, the N-terminal
amino group or side-chain functional group has been
chemically codified to another functional group. For
20 example, aspartic acid-(beta-methyl ester) is an amino acid
analog of aspartic acid; N-ethylglycine is an amino acid
analog of glycine; or alanine carboxamide is an amino acid
analog of alanine.

The term "amino acid residue" refers to radicals
25 having the structure: (1) $-C(O)-R-NH-$, wherein R typically

is $-\text{CH}(\text{R}')-$, wherein R' is an amino acid side chain, typically H or a carbon containing substituent; or (2),



5

wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipercolic acid residues, respectively.

The term "lower" referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms. Such groups may be straight chain or branched chain.

"Pharmaceutically acceptable salt" includes salts of the compounds described herein derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds are useful in both free base and salt form.

In addition, the following abbreviations stand for the following:

"ACN" or " CH_3CN " refers to acetonitrile.

"Boc", "tBoc" or "Tboc" refers to t-butoxy carbonyl.

"DCC" refers to N,N'-dicyclohexylcarbodiimide.

"Fmoc" refers to fluorenylmethoxycarbonyl.

"HBTU" refers to 2-(1H-benzotriazol-1-yl)-
1,1,3,3,-tetramethyluronium hexafluorophosphate.

5 "HOBt" refers to 1-hydroxybenzotriazole monohydrate.

"homoP" or hPro" refers to homoproline.

"MeAla" or "Nme" refers to N-methylalanine.

"naph" refers to naphthylalanine.

"pG" or pGly" refers to pentylglycine.

10 "tBuG" refers to tertiary-butylglycine.

"ThioP" or tPro" refers to thioproline.

3Hyp" refers to 3-hydroxyproline

4Hyp" refers to 4-hydroxyproline

NAG" refers to N-alkylglycine

15 NAPG" refers to N-alkylpentylglycine

"Norval" refers to norvaline

"Norleu" refers to norleucine

20 Preparation of Compounds

The exendins and exendin agonists described herein may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such techniques, an

25 α -N-carbamoyl protected amino acid and an amino acid

attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as
5 dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α -N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the
10 next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein.

The solvents, amino acid derivatives and
15 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, CA). The following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.:
Boc-Arg(Mts), Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu),
20 Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt).
Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, CA). Anisole, dimethylsulfide,
25 phenol, ethanedithiol, and thioanisole may be obtained from

Aldrich Chemical Company (Milwaukee, WI). Air Products and Chemicals (Allentown, PA) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, PA).

5 Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, CA) using the NMP/HOBT (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide
10 Synthesizer, Version 1.3B July 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, CA) with capping. Boc-peptide-resins may be cleaved with HF (-5° C to 0° C, 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the
15 filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville,
20 Kentucky).

 Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10 μ , 2.2 x 25 cm; Vydac, Hesperia, CA) may be used to isolate peptides, and purity
25 may be determined using a C4, C8 or C18 analytical column

(5 μ , 0.46 x 25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH₃CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C, 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, PA). Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried out on a VG-Trio machine.

Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate-containing amino acids and peptides

containing such amino acids, may be prepared using methods known in the art. See, e.g., Bartlett and Landen, Biorg. Chem. 14:356-377 (1986).

5 The compounds described above are useful in view of their pharmacological properties. In particular, the compounds of the invention possess activity as agents to reduce food intake. They can be used to treat conditions or diseases which can be alleviated by reducing food intake.

10 Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. In some cases, it will be convenient to provide an exendin or exendin agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent, such as
15 amylin, an amylin agonist, a CCK, or a leptin, in a single composition or solution for administration together. In other cases, it may be more advantageous to administer the additional agent separately from said exendin or exendin
20 agonist. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E.W.
25 Martin. See also Wang, Y.J. and Hanson, M.A. "Parenteral

Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).

5 Compounds useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution
10 at a pH of about 3.0 to 8.0, preferably at a pH of about 3.5 to 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate
15 physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the
20 bloodstream over many hours or days following transdermal injection or delivery.

The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene
25 glycol, polyols (such as mannitol and sorbitol), or other

inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.

The claimed compositions can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher concentrations of the drug.

Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic

acid, cyclohexylsulfamic acid, and quinic acid. Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which
5 the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

Carriers or excipients can also be used to facilitate
10 administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible
15 solvents. The compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, transmucosally, or by pulmonary inhalation.

20 If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be
25 employed including, for example, acacia powder, a non-ionic

surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).

5 Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of
10 water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.

For use by the physician, the compositions will be provided in dosage unit form containing an amount of an exendin or exendin agonist, for example, exendin-3, and/or
15 exendin-4, with or without another food intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent. Therapeutically effective amounts of an exendin or exendin agonist for use in reducing food intake are those that suppress appetite at a desired level. As will be recognized
20 by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the blood sugar level and other factors.

The effective daily appetite-suppressing dose of the
25 compounds will typically be in the range of about 10 to 30

μ g to about 5 mg/day, preferably about 10 to 30 μ g to about 2 mg/day and more preferably about 10 to 100 μ g to about 1 mg/day, most preferably about 30 μ g to about 500 μ g/day, for a 70 kg patient, administered in a single or divided doses.

5 The exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin whenever the
10 suppression of food intake, or weight lowering is desired, for example, at the first sign of symptoms or shortly after diagnosis of obesity, diabetes mellitus, or insulin-resistance syndrome. Administration may be by injection, preferably subcutaneous or intramuscular. Orally active
15 compounds may be taken orally, however dosages should be increased 5-10 fold.

 The optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or
20 disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm
25 animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.

5

10

15

20

intervals to determine the amount of food eaten.

Figure 1 depicts cumulative food intake over periods of 0.5, 1, 2 and 6hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline, 2 doses of GLP-1, or 4
5 doses of exendin-4. At doses up to 100µg/kg, GLP-1 had no effect on food intake measured over any period, a result consistent with that previously reported (Bhavsar, S.P., et al., Soc. Neurosci. Abstr. 21:460 (188.8) (1995); and Turton, M.D., Nature, 379:69-72, (1996)).

10 In contrast, exendin-4 injections potently and dose-dependently inhibited food intake. The ED₅₀ for inhibition of food intake over 30 min was 1µg/kg, which is a level about as potent as amylin (ED₅₀ 3.6µg/kg) or the prototypical peripheral satiety agent, CCK (ED₅₀ 0.97µg/kg) as measured in
15 this preparation. However, in contrast to the effects of amylin or CCK, which abate after 1-2 hours, the inhibition of food intake with exendin-4 was still present after at least 6 hours after injection.

20 EXAMPLE 2: Exendin Reduced the Food Intake of Obese Mice

All mice (female ob/ob mice) were housed in a stable environment of 22 (±2)° C, 60 (±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with *ad libitum* access
25 to food (Teklad: LM 485) and water except as noted, for at

least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μ l/kg) of either saline or exendin-4 at doses of 0.1, 1.0 and 10 μ g/kg (female ob/ob mice) and were immediately presented with a pre-weighed food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1 -hr, 2-hr and 6-hr intervals to determine the amount of food eaten.

Figure 2 depicts the effect of exendin-4 in the ob/ob mouse model of obesity. The obese mice had a similar food intake-related response to exendin as the normal mice. Moreover, the obese mice were not hypersensitive to exendin, as has been observed with amylin and leptin (Young, A.A., et al., Program and Abstracts, 10th International Congress of Endocrinology, June 12-15, 1996 San Francisco, pg 419 (P2-58)).

EXAMPLE 3: Intracerebroventricular Injections of Exendin

Inhibited Food Intake in Rats

All rats (Harlan Sprague-Dawley) were housed in a stable environment of 22 (\pm 2) $^{\circ}$ C, 60 (\pm 10)% humidity and a 12:12 light:dark cycle; with lights on at 0600. Rats were

obtained from Zivic Miller with an intracerebroventricular cannula (ICV cannula) implanted (coordinates determined by actual weight of animals and referenced to Paxinos, G. and Watson, C. "The Rat Brain in stereotaxic coordinates," second edition. Academic Press) and were individually housed in standard cages with *ad libitum* access to food (Teklad: LM 485) and water for at least one week before the experiments.

All injections were given between the hours of 1700 and 1800. The rats were habituated to the ICV injection procedure at least once before the ICV administration of compound. All rats received an ICV injection (2 μ l/30 seconds) of either saline or exendin-4 at doses of 0.01, 0.03, 0.1, 0.3, and 1.0 μ g. All animals were then presented with pre-weighed food (Teklad LM 485) at 1800, when the lights were turned off. The amount of food left was weighed at 2-hr, 12-hr and 24-hr intervals to determine the amount of food eaten by each animal.

Figure 3 depicts a dose-dependent inhibition of food intake in rats that received doses greater than 0.1 μ g/rat. The ED₅₀ was \approx 0.1 μ g, exendin-4 is thus \approx 100-fold more potent than intracerebroventricular injections of GLP-1 as reported by Turton, M.D., et al. (Nature 379:69-72 (1996)).

EXAMPLE 4: Exendin Agonists Reduced the Food Intake in

Mice

All mice (NIH:Swiss mice) were housed in a stable environment of 22 (± 2)° C, 60 (± 10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed
5 in groups of four in standard cages with *ad libitum* access to food (Teklad: LM 485; Madison, WI) and water except as noted, for at least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed
10 at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μ l/kg) of either saline or test compound at doses of 1, 10, and 100 μ g/kg and immediately presented with a food pellet (Teklad LM 485). The food pellet was
15 weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten.

Figure 4 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-
20 4 (1-30) ("Compound 1") in doses of 1, 10 and 100 μ g/kg.

Figure 5 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-
25 4 (1-30) amide ("Compound 2") in doses of 1, 10 and 100 μ g/kg.

Figure 6 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-4 (1-28) amide ("Compound 3") in doses of 1, 10 and 100 $\mu\text{g/kg}$.

Figure 7 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or ^{14}Leu , ^{25}Phe exendin-4 amide ("Compound 4") in doses of 1, 10 and 100 $\mu\text{g/kg}$.

Figure 8 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or ^{14}Leu , ^{25}Phe exendin-4 (1-28) amide ("Compound 5") in doses of 1, 10 and 100 $\mu\text{g/kg}$.

Figure 9 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or ^{14}Leu , ^{22}Ala , ^{25}Phe exendin-4 (1-28) amide ("Compound 6") in doses of 1, 10 and 100 $\mu\text{g/kg}$.

EXAMPLE 5

Preparation of amidated peptide having SEQ. ID. NO. 9

The above-identified peptide was assembled on 4-(2'-

4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.). In
general, single-coupling cycles were used throughout the
5 synthesis and Fast Moc (HBTU activation) chemistry was
employed. However, at some positions coupling was less
efficient than expected and double couplings were required.
In particular, residues Asp₉, Thr, and Phe₆ all required
double coupling. Deprotection (Fmoc group removal) of the
10 growing peptide chain using piperidine was not always
efficient. Double deprotection was required at positions
Arg₂₀, Val₁₉, and Leu₁₄. Final deprotection of the completed
peptide resin was achieved using a mixture of
triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole
15 (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL)
according to standard methods (Introduction to Cleavage
Techniques, Applied Biosystems, Inc.) The peptide was
precipitated in ether/water (50 mL) and centrifuged. The
precipitate was reconstituted in glacial acetic acid and
20 lyophilized. The lyophilized peptide was dissolved in
water). Crude purity was about 55%.

Used in purification steps and analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a
25 preparative C-18 column and purified (10% to 40% Solvent B

in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 4131.7; found 4129.3.

10

EXAMPLE 6Preparation of Peptide having SEQ. ID. NO. 10

The above-identified peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 25% to 75% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 21.5 minutes. Electrospray Mass Spectrometry (M): calculated 4168.6; found 4171.2.

25

EXAMPLE 7Preparation of Peptide having SEQ. ID. NO. 11

5 The above-identified peptide was assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis were Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9
minutes. Electrospray Mass Spectrometry (M): calculated
15 4147.6; found 4150.2.

EXAMPLE 8Preparation of Peptide having SEQ. ID. NO. 12

20 The above-identified peptide was assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
25 similar way to Example 5. Used in analysis were Solvent A

(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 35% to 65% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 19.7
5 minutes. Electrospray Mass Spectrometry (M): calculated
4212.6; found 4213.2.

EXAMPLE 9

Preparation of Peptide having SEQ. ID. NO. 13

10

The above-identified peptide was assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
15 cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 50% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
20 product peptide having an observed retention time of 16.3
minutes. Electrospray Mass Spectrometry (M): calculated
4262.7; found 4262.4.

EXAMPLE 10

25

Preparation of Peptide having SEQ. ID. NO. 14

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6

15

EXAMPLE 11Preparation of Peptide having SEQ. ID. NO. 15

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7.

5

EXAMPLE 12

Preparation of Peptide having SEQ. ID. NO. 16

The above-identified peptide is assembled on 4-(2'-4'-
10 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
15 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
20 calculated 4172.6

EXAMPLE 13

Preparation of Peptide having SEQ. ID. NO. 17

25 The above-identified peptide is assembled on 4-(2'-4'-

dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
5 similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 4186.6

EXAMPLE 14

Preparation of Peptide having SEQ. ID. NO. 18

15 The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
20 cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
25 then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 4200.7

EXAMPLE 15

5 Preparation of Peptide having SEQ. ID. NO. 19

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
10 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
15 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4200.7

20

EXAMPLE 16

Preparation of Peptide having SEQ. ID. NO. 20

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
25 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using

Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4202.7.

10

EXAMPLE 17

Preparation of Peptide having SEQ. ID. NO. 21

The above-identified peptide is assembled on 4-(2'-4'-
15 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
20 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 4145.6.

EXAMPLE 18Preparation of Peptide having SEQ. ID. NO. 22

5 The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
10 similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 4184.6.

EXAMPLE 19Preparation of Peptide having SEQ. ID. NO. 23

20 The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
25 cleaved from the resin, deprotected and purified in a

similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6.

10

EXAMPLE 20Preparation of Peptide having SEQ. ID. NO. 24

15

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

20

Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7.

25

EXAMPLE 21Preparation of Peptide having SEQ. ID. NO. 25

The above-identified peptide is assembled on 4-(2'-4'-
5 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 4172.6.

EXAMPLE 22Preparation of Peptide having SEQ. ID. NO. 26

20 The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
25 similar way to Example 5. Used in analysis are Solvent A

(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
5 product peptide. Electrospray Mass Spectrometry (M):
calculated 4115.5.

EXAMPLE 23

10 Preparation of Peptide having SEQ. ID. NO. 27

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
15 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4188.6.

25

EXAMPLE 24

Preparation of Peptide having SEQ. ID. NO. 28

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
5 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
10 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4131.6.

15

EXAMPLE 25Preparation of Peptide having SEQ. ID. NO. 29

The above-identified peptide is assembled on 4-(2'-4'-
20 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
25 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 4172.6.

EXAMPLE 26

Preparation of Peptide having SEQ. ID. NO. 30

10 The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a
15 similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6.

EXAMPLE 27

Preparation of Peptide having SEQ. ID. NO. 31

25

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.),
5 cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient
10 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4266.8.

15

EXAMPLE 28Preparation of Peptide having SEQ. ID. NO. 32

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
20 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37 and 36. Used
25 in analysis are Solvent A (0.1% TFA in water) and Solvent B

(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 4246.8.

EXAMPLE 29

Preparation of Peptide having SEQ. ID. NO. 33

10 The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.),
15 cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
20 lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4250.8.

25

EXAMPLE 30

Preparation of Peptide having SEQ. ID. NO. 34

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4234.8.

EXAMPLE 31Preparation of Peptide having SEQ. ID. NO. 35

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31.

Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4209.8.

EXAMPLE 32

Preparation of Peptide having SEQ. ID. NO. 36

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4193.7.

EXAMPLE 33

Preparation of Peptide having SEQ. ID. NO. 37

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
5 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Additional double couplings are
required at the N-methylalanine positions 38, 37, 36 and
10 31. Used in analysis are Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient
30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the
retention time of the product peptide. Electrospray Mass
15 Spectrometry (M): calculated 3858.2.

EXAMPLE 34Preparation of Peptide having SEQ. ID. NO. 38

20 The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
25 similar way to Example 5. Additional double couplings are

required at the N-methylalanine positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3940.3.

10

EXAMPLE 35Preparation of Peptide having SEQ. ID. NO. 39

15

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3801.1.

20

25

EXAMPLE 36

Preparation of C-terminal carboxylic acid Peptides
corresponding to the above C-terminal amide sequences.

5

The above peptides of Examples 5 to 35 are assembled on the so called Wang resin (p-alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin,
10 deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the
15 retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

EXAMPLE 37

20

Preparation of Peptide having SEQ ID NO. 7

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly
Gly-NH₂ [SEQ. ID. NO. 7]

25

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide

norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%.

Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

gave product peptide having an observed retention time of 18.9 minutes. Electrospray Mass Spectrometry (M): calculated 3408.0; found 3408.9.

5

EXAMPLE 38Preparation of Peptide having SEQ ID NO. 40

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
10 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 40]

The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
15 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 40% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9
minutes. Electrospray Mass Spectrometry (M): calculated
3294.7; found 3294.8.

25

EXAMPLE 39Preparation of Peptide having SEQ ID NO. 41

5

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 41]

10

The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 37. Used in analysis were Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 29% to 36% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 20.7
20 minutes. Electrospray Mass Spectrometry (M): calculated
3237.6; found 3240.

EXAMPLE 40

25

Preparation of Peptide having SEQ ID NO. 42

His Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 42]

5

The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
10 cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 36% to 46% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
15 product peptide having an observed retention time of 15.2
minutes. Electrospray Mass Spectrometry (M): calculated
3251.6; found 3251.5.

EXAMPLE 41

20

Preparation of Peptide having SEQ ID NO. 43

His Gly Glu Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
25 Asn-NH₂ [SEQ. ID. NO. 43]

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 13.1 minutes. Electrospray Mass Spectrometry (M): calculated 3207.6; found 3208.3.

15

EXAMPLE 42Preparation of Peptide having SEQ ID NO. 44

His Gly Glu Gly Thr Ala Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 44]

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using

Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
5 Analytical RP-HPLC (gradient 35% to 45% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 12.8
minutes. Electrospray Mass Spectrometry (M): calculated
3161.5; found 3163.

10

EXAMPLE 43Preparation of Peptide having SEQ ID NO. 45

15 His Gly Glu Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 45]

The above-identified amidated peptide was assembled on
20 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis were Solvent
25 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated
5 3221.6; found 3222.7.

EXAMPLE 44

Preparation of Peptide having SEQ ID NO. 46

10

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 46]

15

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
20 a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3
25 minutes. Electrospray Mass Spectrometry (M): calculated

3195.5; found 3199.4.

EXAMPLE 45

5 Preparation of Peptide having SEQ ID NO. 47

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 47]

10 The above-identified amidated peptide was assembled on 4-
(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
15 cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 38% to 48% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
20 product peptide having an observed retention time of 15.7
minutes. Electrospray Mass Spectrometry (M): calculated
3221.6; found 3221.6.

EXAMPLE 46

25 Preparation of Peptide having SEQ ID NO. 48

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 48]

5 The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
10 a similar way to Example 37. Used in analysis were Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 38% to 48% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 18.1
15 minutes. Electrospray Mass Spectrometry (M): calculated
3180.5; found 3180.9.

EXAMPLE 47

20 Preparation of Peptide having SEQ ID NO. 49

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 49]

25

The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)

using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
5 Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.0 minutes. Electrospray Mass Spectrometry (M): calculated 3180.6; found 3182.8.

10

EXAMPLE 48Preparation of Peptide having SEQ ID NO. 50

15 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 50]

The above-identified amidated peptide was assembled on
20 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis were Solvent
25 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated
5 3195.5; found 3195.9.

EXAMPLE 49

Preparation of Peptide having SEQ ID NO. 51

10

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Ala
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 51]

15

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
20 a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9
25 minutes. Electrospray Mass Spectrometry (M): calculated

3179.6; found 3179.0.

EXAMPLE 50

5

Preparation of Peptide having SEQ ID NO. 52

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
10 [SEQ. ID. NO. 52]

The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
15 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis were Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 37% to 47% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.3
minutes. Electrospray Mass Spectrometry (M): calculated
3179.6; found 3180.0.

25

EXAMPLE 51

Preparation of Peptide having SEQ ID NO. 53

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

[SEQ. ID. NO. 53]

5 The above-identified peptide was assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
10 similar way to Example 37. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 37% to 47% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 13.7
15 minutes. Electrospray Mass Spectrometry (M): calculated
3179.6; found 3179.0.

EXAMPLE 52

20 Preparation of Peptide having SEQ ID NO. 54

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

[SEQ. ID. NO. 54]

25

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.0 minutes. Electrospray Mass Spectrometry (M): calculated 3209.6; found 3212.8.

EXAMPLE 53

15

Preparation of Peptide having SEQ ID NO. 55

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 55]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems,

Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3152.5; found 3153.5.

10

EXAMPLE 54Preparation of Peptide having SEQ ID NO. 56

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
15 Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 56]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 35% to 45% Solvent B in
25

Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.1 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3197.7.

5

EXAMPLE 55Preparation of Peptide having SEQ ID NO. 57

10 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Ala Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 57]

15 The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis were Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 38% to 48% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 10.9
minutes. Electrospray Mass Spectrometry (M): calculated
25 3179.6; found 3180.5.

EXAMPLE 56Preparation of Peptide having SEQ ID NO. 58

5

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂
[SEQ. ID. NO. 58]

10

The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 37. Used in analysis were Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 32% to 42% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.5
20 minutes. Electrospray Mass Spectrometry (M): calculated
3161.5; found 3163.0.

EXAMPLE 57

25

Preparation of Peptide having SEQ ID NO. 59

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn-NH₂

[SEQ. ID. NO. 59]

The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis were Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
10 Analytical RP-HPLC (gradient 32% to 42% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 19.5
minutes. Electrospray Mass Spectrometry (M): calculated
3195.5; found 3199.

15

EXAMPLE 58

Preparation of Peptide having SEQ ID NO. 60

20 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Ala Asn-NH₂
[SEQ. ID. NO. 60]

The above-identified amidated peptide was assembled on
25 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3183.7.

EXAMPLE 59

Preparation of Peptide having SEQ ID NO. 61

15

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala-NH₂
[SEQ. ID. NO. 61]

20

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent

25

A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 34% to 44% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 22.8
5 minutes. Electrospray Mass Spectrometry (M): calculated
3194.6; found 3197.6.

EXAMPLE 60

10 Preparation of Peptide having SEQ ID NO. 62

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO. 62]

15

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
20 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
25 then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 4099.6.

EXAMPLE 61

5

Preparation of Peptide having SEQ ID NO. 63

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
10 Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO. 63]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
15 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4042.5.

25

EXAMPLE 62

Preparation of Peptide having SEQ ID NO. 64

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
5 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 64]

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
10 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4002.4

20

EXAMPLE 63Preparation of Peptide having SEQ ID NO. 65

25 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu

Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 65]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 3945.4.

EXAMPLE 64

Preparation of Peptide having SEQ ID NO. 66

20

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 66]

25

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
5 a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3905.3.

EXAMPLE 65

15 Preparation of Peptide having SEQ ID NO. 67

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 67]

20

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
25 Inc.), cleaved from the resin, deprotected and purified in

a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3848.2.

EXAMPLE 66

10

Preparation of Peptide having SEQ ID NO. 68

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 68]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3808.2.

5

EXAMPLE 67Preparation of Peptide having SEQ ID NO. 69

10 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 69]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
20 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3751.1.

EXAMPLE 68Preparation of Peptide having SEQ ID NO. 70

5

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly-NH₂ [SEQ. ID. NO. 70]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3737.1.

EXAMPLE 69

25

Preparation of Peptide having SEQ ID NO. 71

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly-NH₂ [SEQ. ID. NO. 71]

5

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
10 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
15 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3680.1.

EXAMPLE 70

20

Preparation of Peptide having SEQ ID NO. 72

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
25 Pro Ser Ser-NH₂ [SEQ. ID. NO. 72]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1

15

EXAMPLE 71Preparation of Peptide having SEQ ID NO. 73

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
20 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser-NH₂ [SEQ. ID. NO. 73]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A

(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3623.0.

EXAMPLE 72

10 Preparation of Peptide having SEQ ID NO. 74

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser-NH₂ [SEQ. ID. NO. 74]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the

25

product peptide. Electrospray Mass Spectrometry (M):
calculated 3593.0

EXAMPLE 73

5

Preparation of Peptide having SEQ ID NO. 75

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
10 Pro Ser-NH₂ [SEQ. ID. NO. 75]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
15 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3535.9

25

EXAMPLE 74

Preparation of Peptide having SEQ ID NO. 76

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
5 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro-NH₂ [SEQ. ID. NO. 76]

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
10 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3505.9.

20

EXAMPLE 75Preparation of Peptide having SEQ ID NO. 77

25 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu

Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro-NH₂ [SEQ. ID. NO. 77]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 3448.8.

EXAMPLE 76

Preparation of Peptide having SEQ ID NO. 78

20

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly
Gly-NH₂ [SEQ. ID. NO. 78]

25

The above-identified peptide is assembled on 4-(2'-4'-

dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
5 similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3351.7.

EXAMPLE 77

15

Preparation of Peptide having SEQ ID NO. 79

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly-NH₂
20 [SEQ. ID. NO. 79]

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
25 Fmoc-protected amino acids (Applied Biosystems, Inc.),

cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3351.8.

10

EXAMPLE 78Preparation of Peptide having SEQ ID NO. 80

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
15 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly-NH₂
[SEQ. ID. NO. 80]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
25 Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3294.7.

5

EXAMPLE 79Preparation of Peptide having SEQ ID NO. 81

10 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
tPro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID. NO. 81]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Double couplings are required
20 at residues 37,36 and 31. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
25 product peptide. Electrospray Mass Spectrometry (M):

calculated 4197.1.

EXAMPLE 80

5 Preparation of Peptide having SEQ ID NO. 82

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID. NO. 82]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
15 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Double couplings are required
at residues 37, 36 and 31. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4179.1.

25

EXAMPLE 81

Preparation of Peptide having SEQ ID NO. 83

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
5 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
NMeala Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 83]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Double couplings are required
at residues 36 and 31. Used in analysis are Solvent A (0.1%
15 TFA in water) and Solvent B (0.1% TFA in ACN). Analytical
RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30
minutes) of the lyophilized peptide is then carried out to
determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3948.3.

20

EXAMPLE 82Preparation of Peptide having SEQ ID NO. 84

25 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu

Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
NMeala Ser Ser Gly Ala NMeala Nmeala-NH₂ [SEQ. ID. NO. 84]

The above-identified amidated peptide is assembled on
5 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Double couplings are required
10 at residues 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical
RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30
minutes) of the lyophilized peptide is then carried out to
determine the retention time of the product peptide.
15 Electrospray Mass Spectrometry (M): calculated 3840.1.

EXAMPLE 83

Preparation of Peptide having SEQ ID NO. 85

20

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
hPro Ser Ser Gly Ala hPro hPro-NH₂ [SEQ. ID. NO. 85]

25

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
5 a similar way to Example 37. Double couplings are required
at residues 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical
RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30
minutes) of the lyophilized peptide is then carried out to
10 determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4050.1.

EXAMPLE 84

15 Preparation of Peptide having SEQ ID NO. 86

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
hPro Ser Ser Gly Ala hPro-NH₂ [SEQ. ID. NO. 86]

20

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
25 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. A double coupling is required

at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to
5 determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3937.1

EXAMPLE 85

10 Preparation of Peptide having SEQ ID NO. 87

Arg Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 87]

15

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
20 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
25 then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 3827.2.

EXAMPLE 86

5

Preparation of Peptide having SEQ ID NO. 88

His Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly
10 Gly-NH₂ [SEQ. ID. NO. 88]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
15 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3394.8.

25

EXAMPLE 87

Preparation of Peptide having SEQ ID NO. 89

His Gly Glu Gly Thr Naphthylala Thr Ser Asp Leu Ser Lys Gln
5 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 89]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3289.5.

20

EXAMPLE 88Preparation of Peptide having SEQ ID NO. 90

25 His Gly Glu Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met Glu

Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 90]

The above-identified amidated peptide is assembled on
5 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 3280.7.

EXAMPLE 89

Preparation of Peptide having SEQ ID NO. 91

20

His Gly Glu Gly Thr Phe Ser Thr Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 91]

25

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
5 a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3294.7.

EXAMPLE 90

15 Preparation of Peptide having SEQ ID NO. 92

His Gly Glu Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met Ala
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 92]

20 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
25 a similar way to Example 37. Used in analysis are Solvent A

(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3250.7.

EXAMPLE 91

10 Preparation of Peptide having SEQ ID NO. 93

His Gly Glu Gly Thr Phe Thr Ser Asp pentylgly Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 93]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
20 a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is
25 then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 3253.5.

EXAMPLE 92

5

Preparation of Peptide having SEQ ID NO. 94

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Phe Leu Lys
10 Asn-NH₂ [SEQ. ID. NO. 94]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
15 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3289.5.

25

EXAMPLE 93

Preparation of Peptide having SEQ ID NO. 95

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
5 Glu Glu Ala Val Arg Leu Phe tButylgly Glu Trp Leu Lys Asn-
NH₂ [SEQ. ID. NO. 95]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3183.4.

20

EXAMPLE 94Preparation of Peptide having SEQ ID NO. 96

25 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu

Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 96]

The above-identified amidated peptide is assembled on
5 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 37. Used in analysis are Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 3237.6.

EXAMPLE 95

Preparation of Peptide having SEQ ID NO. 97

20

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser-NH₂ [SEQ. ID. NO. 97]

25

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
5 a similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3637.9.

EXAMPLE 96

15 Preparation of Peptide having SEQ ID NO. 98

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly-NH₂
[SEQ. ID. NO. 98]

20

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
25 Inc.), cleaved from the resin, deprotected and purified in

a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3309.7.

EXAMPLE 97

10

Preparation of Peptide having SEQ ID NO. 99

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
15 hPro Ser Ser Gly Ala hPro hPro-NH₂ [SEQ. ID. NO. 99]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical
20 RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30
25

minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3711.1.

5

EXAMPLE 98

Preparation of C-terminal carboxylic acid peptides corresponding to the above C-terminal amide sequences for
10 SEQ ID NOS. 7, 40-61, 68-75, 78-80 and 87-96

Peptides having the sequences of SEQ ID NOS. 7, 40-61, 68-75, 78-80 and 87-96 are assembled on the so called Wang resin (p-alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g))
15 using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

EXAMPLE 99

Preparation of C-terminal carboxylic acid peptides
corresponding to the above C-terminal amide sequences for
5 SEQ ID NOS. 62-67, 76, 77 and 81-86

Peptides having the sequences of SEQ ID NOS. 62-67,
76, 77 and 81-86 are assembled on the 2-
chlorotritylchloride resin (200-400 mesh), 2% DVB
10 (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino
acids (Applied Biosystems, Inc.), cleaved from the resin,
deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient
15 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the
retention time of the product peptide. Electrospray Mass
Spectrometry provides an experimentally determined (M).

20

EXAMPLE 100

Preparation of Peptide having SEQ ID NO. 100

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
25 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

[SEQ. ID. NO. 100]

The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
5 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.). In
general, single-coupling cycles were used throughout the
synthesis and Fast Moc (HBTU activation) chemistry was
employed. Deprotection (Fmoc group removal) of the growing
10 peptide chain was achieved using piperidine. Final
deprotection of the completed peptide resin was achieved
using a mixture of triethylsilane (0.2 mL), ethanedithiol
(0.2 mL), anisole (0.2 mL), water (0.2 mL) and
trifluoroacetic acid (15 mL) according to standard methods
15 (Introduction to Cleavage Techniques, Applied Biosystems,
Inc.) The peptide was precipitated in ether/water (50 mL)
and centrifuged. The precipitate was reconstituted in
glacial acetic acid and lyophilized. The lyophilized
peptide was dissolved in water). Crude purity was about
20 75%.

Used in purification steps and analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a
preparative C-18 column and purified (10% to 40% Solvent B
25 in Solvent A over 40 minutes). Purity of fractions was

determined isocratically using a C-18 analytical column.
Pure fractions were pooled furnishing the above-identified
peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
5 gave product peptide having an observed retention time of
19.2 minutes. Electrospray Mass Spectrometry (M):
calculated 3171.6; found 3172.

EXAMPLE 101

10

Preparation of Peptide having SEQ ID NO. 101

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
15 [SEQ. ID. NO. 101]

15

The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
20 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 100. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 36% to 46% Solvent B in
25 Solvent A over 30 minutes) of the lyophilized peptide gave

product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.

5

EXAMPLE 102Preparation of Peptide having SEQ ID NO. 102

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
10 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 102]

The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
15 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 100. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 37% to 47% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 12.2
minutes. Electrospray Mass Spectrometry (M): calculated
3251.6; found 3253.3.

25

EXAMPLE 103Preparation of Peptide having SEQ ID NO. 103

5 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 103]

10 The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 100. Used in analysis were Solvent A
15 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 35% to 45% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 16.3
minutes. Electrospray Mass Spectrometry (M): calculated
20 3193.6; found 3197.

EXAMPLE 104Preparation of Peptide having SEQ ID NO. 104

25

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 104]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
10 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 3228.6.

EXAMPLE 105

20 Preparation of Peptide having SEQ ID NO. 105

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 105]

25

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3234.7.

EXAMPLE 106

15

Preparation of Peptide having SEQ ID NO. 106

20

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 106]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems,

Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3308.7.

10

EXAMPLE 107Preparation of Peptide having SEQ ID NO. 107

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met Glu
15 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 107]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
20 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
25 Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3250.7

5

EXAMPLE 108Preparation of Peptide having SEQ ID NO. 108

10 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 108]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3252.6.

EXAMPLE 109Preparation of Peptide having SEQ ID NO. 109

5

Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 109]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3200.6.

EXAMPLE 110

25

Preparation of Peptide having SEQ ID NO. 110

Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 110]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
10 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 3143.5.

EXAMPLE 111

20

Preparation of Peptide having SEQ ID NO. 111

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
25 [SEQ. ID. NO. 111]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3214.6.

15

EXAMPLE 112Preparation of Peptide having SEQ ID NO. 112

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 112]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g).

using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.

10

EXAMPLE 113

Preparation of Peptide having SEQ ID NO. 113

15 Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 113]

The above-identified amidated peptide is assembled on
20 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent
25 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3184.6.

EXAMPLE 114

Preparation of Peptide having SEQ ID NO. 114

10

Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 114]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
20 a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the
25 product peptide. Electrospray Mass Spectrometry (M):

calculated 3127.5.

EXAMPLE 115

5 Preparation of Peptide having SEQ ID NO. 115

Ala Gly Asp Gly Thr NaphthylAla Thr Ser Asp Leu Ser Lys Gln
Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn-NH₂ [SEQ. ID. NO. 115]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
15 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
20 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3266.4.

EXAMPLE 116

25

Preparation of Peptide having SEQ ID NO. 116

Ala Gly Asp Gly Thr Naphthylala Thr Ser Asp Leu Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
5 Asn-NH₂ [SEQ. ID. NO. 116]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
10 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
15 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3209.4.

20

EXAMPLE 117Preparation of Peptide having SEQ ID NO. 117

Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met Glu
25 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

[SEQ. ID. NO. 117]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
10 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3200.6.

15

EXAMPLE 118

Preparation of Peptide having SEQ ID NO. 118

20 Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 118]

The above-identified amidated peptide is assembled on
25 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.

EXAMPLE 119

Preparation of Peptide having SEQ ID NO. 119

Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 119]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in

a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3198.6.

EXAMPLE 120

10

Preparation of Peptide having SEQ ID NO. 120

Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

15 [SEQ. ID. NO. 120]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is

25

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3141.5.

5

EXAMPLE 121Preparation of Peptide having SEQ ID NO. 121

Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met Glu
10 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 121]

The above-identified peptide is assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
15 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 100. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3170.6.

25

EXAMPLE 122Preparation of Peptide having SEQ ID NO. 122

5 Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu Glu
 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
 [SEQ. ID. NO. 122]

 The above-identified amidated peptide is assembled on
10 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
 using Fmoc-protected amino acids (Applied Biosystems,
 Inc.), cleaved from the resin, deprotected and purified in
 a similar way to Example 100. Used in analysis are Solvent
15 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
 Solvent A over 30 minutes) of the lyophilized peptide is
 then carried out to determine the retention time of the
 product peptide. Electrospray Mass Spectrometry (M):
20 calculated 3113.5.

EXAMPLE 123Preparation of Peptide having SEQ ID NO. 123

25

Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 123]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
10 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 3228.6.

EXAMPLE 124

20 Preparation of Peptide having SEQ ID NO. 124

Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 124]

25

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3171.6.

EXAMPLE 125

15

Preparation of Peptide having SEQ ID NO. 125

Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 125]

25

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems,

Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.

10

EXAMPLE 126Preparation of Peptide having SEQ ID NO. 126

Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu
15 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 126]

The above-identified amidated peptiden is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.4.

5

EXAMPLE 127Preparation of Peptide having SEQ ID NO. 127

10 Ala Gly Asp Gly Thr Phe Thr Ser Asp Pentylgly Ser Lys Gln
Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn-NH₂ [SEQ. ID. NO. 127]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3230.4.

EXAMPLE 128Preparation of Peptide having SEQ ID NO. 128

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Pentylgly Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 128]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3198.6.

EXAMPLE 129

25

Preparation of Peptide having SEQ ID NO. 129

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 129]

5

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
10 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
15 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3141.5.

20

EXAMPLE 130

Preparation of Peptide having SEQ ID NO. 130

25

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 130]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
5 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
10 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3157.5.

15

EXAMPLE 131Preparation of Peptide having SEQ ID NO. 131

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Met Glu
20 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 131]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
25 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)

using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.4.

10

EXAMPLE 132

Preparation of Peptide having SEQ ID NO. 132

15 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 132]

20 The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent
25 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3157.6.

EXAMPLE 133

Preparation of Peptide having SEQ ID NO. 133

10

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 133]

15

The above-identified amidated peptide is assembled on 4-(2''-4''-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
20 a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the
25 product peptide. Electrospray Mass Spectrometry (M):

calculated 3100.5.

EXAMPLE 134

5 Preparation of Peptide having SEQ ID NO. 134

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 134]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
15 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
20 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3100.5.

EXAMPLE 135

25

Preparation of Peptide having SEQ ID NO. 135

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
5 [SEQ. ID. NO. 135]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
10 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
15 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3154.5.

20

EXAMPLE 136Preparation of Peptide having SEQ ID NO. 136

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala Glu
25 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

[SEQ. ID. NO. 136]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
10 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3115.5.

15

EXAMPLE 137

Preparation of Peptide having SEQ ID NO. 137

20 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Pentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
Lys Asn-NH₂ [SEQ. ID. NO. 137]

The above-identified amidated peptide is assembled on
25 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3212.4.

EXAMPLE 138

Preparation of Peptide having SEQ ID NO. 138

15

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Pentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu
Lys Asn-NH₂ [SEQ. ID. NO. 138]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent

25

A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
5 product peptide. Electrospray Mass Spectrometry (M):
calculated 3173.4.

EXAMPLE 139

Preparation of Peptide having SEQ ID NO. 139

10

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Ala
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 139]

15

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3156.6.

EXAMPLE 140Preparation of Peptide having SEQ ID NO. 140

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Ala
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 140]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3099.5.

EXAMPLE 141

25

Preparation of Peptide having SEQ ID NO. 141

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Ala Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 141]

5

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
10 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
15 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3156.6.

EXAMPLE 142

20

Preparation of Peptide having SEQ ID NO. 142

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
25 [SEQ. ID. NO. 142]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.

EXAMPLE 143

15

Preparation of Peptide having SEQ ID NO. 143

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Ala Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 143]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems,

Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.

10

EXAMPLE 144Preparation of Peptide having SEQ ID NO. 144

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
15 Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 144]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
25

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.

5

EXAMPLE 145Preparation of Peptide having SEQ ID NO. 145

10 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Ala Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 145]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3186.6.

25

EXAMPLE 146Preparation of Peptide having SEQ ID NO. 146

5 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 146]

10 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
15 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
20 calculated 3129.5.

EXAMPLE 147Preparation of Peptide having SEQ ID NO. 147

25 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu

Glu Glu Ala Val Ala Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 147]

The above-identified amidated peptide is assembled on
5 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
10 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 3129.5.

EXAMPLE 148

Preparation of Peptide having SEQ ID NO. 148

20 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 148]

25 The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
5 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3072.4.

EXAMPLE 149

15 Preparation of Peptide having SEQ ID NO. 149

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Ala Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 149]

20

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
25 Inc.), cleaved from the resin, deprotected and purified in

a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.

EXAMPLE 150

10

Preparation of Peptide having SEQ ID NO. 150

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 150]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.

5

EXAMPLE 151Preparation of Peptide having SEQ ID NO. 151

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
10 Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Trp Leu Lys
Asn-NH₂ [SEQ. ID. NO. 151]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3266.4.

25

EXAMPLE 152Preparation of Peptide having SEQ ID NO. 152

5 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 152]

The above-identified amidated peptide is assembled on
10 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
15 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
20 calculated 3209.4.

EXAMPLE 153Preparation of Peptide having SEQ ID NO. 153

25

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Val Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 153]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
10 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 3200.6.

EXAMPLE 154

20 Preparation of Peptide having SEQ ID NO. 154

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Val Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 154]

25

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.

EXAMPLE 155

15

Preparation of Peptide having SEQ ID NO. 155

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe tButylgly Glu Trp Leu Lys Asn-
NH₂ [SEQ. ID. NO. 155]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems,

25

Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3216.5.

10

EXAMPLE 156Preparation of Peptide having SEQ ID NO. 156

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
15 Glu Glu Ala Val Arg Leu Phe tButylgly Glu Phe Leu Lys Asn-
NH₂ [SEQ. ID. NO. 156]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in.
25

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3159.4.

5

EXAMPLE 157Preparation of Peptide having SEQ ID NO. 157

10 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Asp Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 157]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3200.6.

EXAMPLE 158Preparation of Peptide having SEQ ID NO. 158

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 158]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent

15

A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3143.5.

20

EXAMPLE 159

25

Preparation of Peptide having SEQ ID NO. 159

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂
[SEQ. ID. NO. 159]

5

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
10 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
15 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3099.5.

EXAMPLE 160

20

Preparation of Peptide having SEQ ID NO. 160

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂
25 [SEQ. ID. NO. 160]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3081.4.

15

EXAMPLE 161Preparation of Peptide having SEQ ID NO. 161

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Ala Lys Asn-NH₂
[SEQ. ID. NO. 161]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)

using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

- 5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.

10

EXAMPLE 162

Preparation of Peptide having SEQ ID NO. 162

- 15 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn-NH₂
[SEQ. ID. NO. 162]

- The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
20 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
25 Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.

5

EXAMPLE 163Preparation of Peptide having SEQ ID NO. 163

10 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Ala Asn-NH₂
[SEQ. ID. NO. 163]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3157.5.

EXAMPLE 164Preparation of Peptide having SEQ ID NO. 164

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Ala Asn-NH₂
[SEQ. ID. NO. 164]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

15

Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the

20

product peptide. Electrospray Mass Spectrometry (M):
calculated 3100.4.

EXAMPLE 165

25

Preparation of Peptide having SEQ ID NO. 165

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Ala-NH₂
[SEQ. ID. NO. 165]

5

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
10 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
15 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3171.6.

EXAMPLE 166

20

Preparation of Peptide having SEQ ID NO. 166

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala-NH₂
25 [SEQ. ID. NO. 166]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
5 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
10 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3114.5.

15

EXAMPLE 167Preparation of Peptide having SEQ ID NO. 167

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
20 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO. 167]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
25 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)

using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4033.5.

10

EXAMPLE 168

Preparation of Peptide having SEQ ID NO. 168

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
15 Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO. 168]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
20 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
25 Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3984.4.

5

EXAMPLE 169

Preparation of Peptide having SEQ ID NO. 169

10 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 169]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 4016.5.

EXAMPLE 170Preparation of Peptide having SEQ ID NO. 170

5

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 170]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
15 a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3861.3.

EXAMPLE 171

25

Preparation of Peptide having SEQ ID NO. 171

Ala Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 171]

5

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
10 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
15 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3746.1.

EXAMPLE 172

20

Preparation of Peptide having SEQ ID NO. 172

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
25 Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 172]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3742.1.

15

EXAMPLE 173Preparation of Peptide having SEQ ID NO. 173

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 173]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)

using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

- 5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3693.1.

10

EXAMPLE 174

Preparation of Peptide having SEQ ID NO. 174

- 15 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly-NH₂ [SEQ. ID. NO. 174]

- 20 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
25 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3751.2.

EXAMPLE 175

Preparation of Peptide having SEQ ID NO. 175

10

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser-NH₂ [SEQ. ID. NO. 175]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in
20 a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

20

25

Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):

calculated 3634.1.

EXAMPLE 176

5 Preparation of Peptide having SEQ ID NO. 176

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser-NH₂ [SEQ. ID. NO. 176]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
15 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
20 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3526.9.

EXAMPLE 177

25

Preparation of Peptide having SEQ ID NO. 177

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
5 Pro Ser-NH₂ [SEQ. ID. NO. 177]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
10 using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
15 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3477.9.

20

EXAMPLE 178Preparation of Peptide having SEQ ID NO. 178

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
25 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly

Pro-NH₂ [SEQ. ID. NO. 178]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
10 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3519.9.

15

EXAMPLE 179

Preparation of Peptide having SEQ ID NO. 179

20 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly
Gly-NH₂ [SEQ. ID. NO. 179]

The above-identified amidated peptide is assembled on
25 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3307.7.

EXAMPLE 180

Preparation of Peptide having SEQ ID NO. 180

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly-NH₂
[SEQ. ID. NO. 180]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent

A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
5 product peptide. Electrospray Mass Spectrometry (M):
calculated 3186.5.

EXAMPLE 181

10 Preparation of Peptide having SEQ ID NO. 181

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
tPro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID. NO. 181]

15

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
20 Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Double couplings are required
at residues 37,36 and 31. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
25 Solvent A over 30 minutes) of the lyophilized peptide is

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4121.1.

5

EXAMPLE 182Preparation of Peptide having SEQ ID NO. 182

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
10 Pro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID. NO. 182].

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, 15 Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4173.2.

25

EXAMPLE 183Preparation of Peptide having SEQ ID NO. 183

5 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
NMeala Ser Ser Gly Ala NMeala NMeala-NH₂ [SEQ. ID. NO. 183]

The above-identified amidated peptide is assembled on
10 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Compound 1. Double couplings are required
15 at residues 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical
RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30
minutes) of the lyophilized peptide is then carried out to
determine the retention time of the product peptide.
20 Electrospray Mass Spectrometry (M): calculated 3796.1.

EXAMPLE 184Preparation of Peptide having SEQ ID NO. 184

25

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
hPro Ser Ser Gly Ala hPro-NH₂ [SEQ. ID. NO. 184]

- 5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
10 a similar way to Example 100. A double coupling is required
at residue 31. Used in analysis are Solvent A (0.1% TFA in
water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30
minutes) of the lyophilized peptide is then carried out to
15 determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3871.1.

EXAMPLE 185

- 20 Preparation of Peptide having SEQ ID NO. 185

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 185]

25

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3750.2.

EXAMPLE 186

15

Preparation of Peptide having SEQ ID NO. 186

His Gly Asp Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly
20 Gly-NH₂ [SEQ. ID. NO. 186]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems,

25

Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3408.8.

10

EXAMPLE 187Preparation of Peptide having SEQ ID NO. 187

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu
15 Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH₂ [SEQ. ID. NO. 187]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
25

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4120.6.

5

EXAMPLE 188

Preparation of Peptide having SEQ ID NO. 188

10 Ala Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH₂ [SEQ. ID. NO. 188]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g)
using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in
a similar way to Example 100. Used in analysis are Solvent
20 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 4005.5...

EXAMPLE 189Preparation of C-terminal carboxylic acid peptides

5 corresponding to the above C-terminal amide sequences for
 Peptides having SEQ ID NOS. 100-166, 172-177, 179-180 and
 185-188.

 C-terminal carboxylic acid peptides corresponding to
10 amidated having SEQ ID NOS. 100-166, 172-177, 179-180 and
 185-188 are assembled on the so called Wang resin (p-
 alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g)) using
 Fmoc-protected amino acids (Applied Biosystems, Inc.),
 cleaved from the resin, deprotected and purified in a
15 similar way to that described in Example 100. Used in
 analysis are Solvent A (0.1% TFA in water) and Solvent B
 (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
 Solvent B in Solvent A over 30 minutes) of the lyophilized
 peptide is then carried out to determine the retention time
20 of the product peptide. Electrospray Mass Spectrometry
 provides an experimentally determined (M).

EXAMPLE 190

25

Preparation of C-terminal carboxylic acid peptides
corresponding to the above C-terminal amide sequences for
Peptides having SEQ ID NOS. 167-171, 178 and 181-184.

5 C-terminal carboxylic acid peptides corresponding to
amidated SEQ ID NOS. 167-171, 178 and 181-184 are assembled
on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB
(Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino
acids (Applied Biosystems, Inc.), cleaved from the resin,
10 deprotected and purified in a similar way to that described
in Example 100. Used in analysis are Solvent A (0.1% TFA in
water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30
minutes) of the lyophilized peptide is then carried out to
15 determine the retention time of the product peptide.
Electrospray Mass Spectrometry provides an experimentally
determined (M).

20 Various modifications of the invention in addition to
those shown and described herein will become apparent to
those skilled in the art from the foregoing description and
fall within the scope of the following claims.

WE CLAIM:

1. A method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
2. The method according to claim 1 wherein said exendin or exendin agonist is administered parenterally.
3. The method according to claim 2 wherein said parenteral administration is by injection.
4. The method according to claim 3 wherein the injection is a peripheral injection.
5. The method according to claim 1 wherein about 10 μ g-30 μ g to about 5mg of the exendin or exendin agonist is administered per day.
6. The method according to claim 1 wherein about 10 μ g-30 μ g to about 2 mg of the exendin or exendin agonist is administered per day.
7. The method according to claim 1, wherein about 30 μ g to about 500 μ g of the exendin or exendin agonist is administered per day.
8. The method of claim 1 wherein said condition or disorder is obesity.
9. The method of claim 1 wherein said condition or disorder is Type II diabetes.
10. The method of claim 1 wherein said subject is

human.

11. The method of claim 1 wherein said condition or disorder is an eating disorder.

12. The method of claim 1 wherein said condition or disorder is insulin-resistance syndrome.

13. A method for reducing the appetite of a subject comprising administering to said subject an appetite-lowering amount of an exendin or an exendin agonist.

14. A method for reducing the weight of a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

15. A method for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

16. The method according to any of claims 1-15 wherein said exendin is exendin-3.

17. The method according to any of claims 1-15 wherein said exendin is exendin-4.

18. The method according to any of claims 1-15 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu,²⁵Phe exendin-4 amide, ¹⁴Leu,²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu,²²Ala,²⁵Phe exendin-4 (1-28) amide.

19. The method according to any of claims 1-15, further comprising administering a therapeutically effective

amount of one or more compounds selected from the group consisting essential of an amylin agonist, a leptin, and a CCK.

20. The method according to any of claims 1-15 wherein
5 said exendin agonist is an exendin agonist according to Formula I.

21. The method according to any of claims 1-15 wherein
said exendin agonist is an exendin agonist according to Formula II.

10 22. The method according to any of claims 1-15 wherein
said exendin agonist is an exendin agonist according to Formula III.

23. A pharmaceutical composition for use in the
treatment of conditions or disorders associated with
15 hypernutrition comprising a therapeutically effective amount
of an exendin or exendin agonist in association with a
pharmaceutically acceptable carrier.

24. The pharmaceutical composition according to claim
21, wherein said exendin is exendin-3.

20 25. The pharmaceutical composition according to claim
21 wherein said exendin is exendin-4.

26. The pharmaceutical composition according to claim
21 wherein said exendin agonist is selected from the group
consisting of exendin-4 (1-30), exendin-4 (1-30) amide,
25 exendin-4 (1-28) amide, ¹⁴Leu, ²⁵Phe exendin-4 amide, ¹⁴Leu, ²⁵Phe

exendin-4 (1-28) amide, and ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide.

27. The pharmaceutical composition of claim 21 wherein said therapeutically effective amount is a therapeutically effective amount for a human subject.

28. A pharmaceutical composition for use in reducing the appetite of a subject comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.

29. A pharmaceutical composition for use in reducing the weight of a subject comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.

30. A pharmaceutical composition for use in lowering the plasma lipid level of a subject comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.

31. The pharmaceutical composition according to any of claims 21-28, further comprising a therapeutically effective amount of one or more compounds selected from the group consisting essentially of an amylin agonist, a leptin, and a CCK.





FIGURE 1

Effect of Exendin-4 on Food Intake in
Female ob/ob Mice
Mean \pm S.E.



All Injections given IP (5 ml/kg) at T=0 minutes

FIGURE 2







FIGURE 3

**FIGURE 4**





FIGURE 5

**FIGURE 6**




FIGURE 7




FIGURE 8

Effect of Compound 6 on Food Intake
in NIH/SW Mice
Mean \pm S.E.




FIGURE 9

1 Xaa₁ Xaa₂ Xaa₃ Gly Thr Xaa₄ Xaa₅ Xaa₆ Xaa₇ Ser Lys Gln Xaa₈ Glu Glu Ala Val Arg Leu 15 20
 Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Leu Lys Asn Gly Gly Xaa₁₄ Ser Ser Gly Ala Xaa₁₅ Xaa₁₆ Xaa₁₇ Xaa₁₈-Z 25 30 35

[SEQ. ID. NO.]	Xaa ₁	Xaa ₂	Xaa ₃	Xaa ₄	Xaa ₅	Xaa ₆	Xaa ₇	Xaa ₈	Xaa ₉	Xaa ₁₀	Xaa ₁₁	Xaa ₁₂	Xaa ₁₃	Xaa ₁₄	Xaa ₁₅	Xaa ₁₆	Xaa ₁₇	Xaa ₁₈	Z
9	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
10	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
11	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
12	Tyr	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
13	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Tyr	NH ₂
14	His	Gly	Asp	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
15	His	Gly	Glu	naph	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
16	His	Gly	Glu	Phe	Ser	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
17	His	Gly	Glu	Phe	Ser	Thr	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
18	His	Gly	Glu	Phe	Thr	Thr	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
19	His	Gly	Glu	Phe	Thr	Ser	Glu	Leu	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
20	His	Gly	Glu	Phe	Thr	Ser	Asp	pGly	Met	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
21	His	Gly	Glu	Phe	Thr	Ser	Asp	pGly	Leu	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
22	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	pGly	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂

FIGURE 10
(Sheet 1 of 2)

[SEQ. ID. NO.]	Xaa ₁	Xaa ₂	Xaa ₃	Xaa ₄	Xaa ₅	Xaa ₆	Xaa ₇	Xaa ₈	Xaa ₉	Xaa ₁₀	Xaa ₁₁	Xaa ₁₂	Xaa ₁₃	Xaa ₁₄	Xaa ₁₅	Xaa ₁₆	Xaa ₁₇	Xaa ₁₈	Z
23	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	pGly	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
24	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	naph	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
25	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Val	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
26	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Val	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH
27	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	tBuG	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
28	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	tBuG	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
29	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Asp	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
30	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
31	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	tPro	tPro	tPro	tPro	Ser	NH ₂
32	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	tPro	tPro	tPro	Ser	NH ₂
33	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	hPro	hPro	hPro	hPro	Ser	NH ₂
34	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	hPro	hPro	hPro	Ser	NH ₂
35	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	tPro	tPro	tPro	tPro	Ser	NH ₂
36	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	hPro	hPro	hPro	hPro	Ser	NH ₂
37	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	MeAla	MeAla	MeAla	MeAla	Ser	NH
38	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	MeAla	MeAla	MeAla	Ser	NH
39	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	MeAla	MeAla	MeAla	MeAla	Ser	NH

FIGURE 10
(Sheet 2 of 2)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00449

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/16

US CL : 514/2, 866

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 866

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,424,286 A (ENG) 13 June 1995 see entire document.	1-31

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 MAY 1998

Date of mailing of the international search report

29 MAY 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Zohreh Fay

Telephone No. (703) 308-1235



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/16		(11) International Publication Number: WO 98/30231
A1		(43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US98/00449 (22) International Filing Date: 7 January 1998 (07.01.98) (30) Priority Data: 60/034,905 7 January 1997 (07.01.97) US 60/055,404 8 August 1997 (08.08.97) US 60/066,029 14 November 1997 (14.11.97) US 60/065,442 14 November 1997 (14.11.97) US (71) Applicant: AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Centre Drive, San Diego, CA 92121 (US). (72) Inventors: BEELEY, Nigel, Robert, Arnold; 227 Loma Corta Drive, Solana Beach, CA 92075 (US). PRICKETT, Kathryn, S.; 7612 Trailbrush Terrace, San Diego, CA 92126 (US). BHAVSAR, Sunil; Apartment #7, 917 Torrance Street, San Diego, CA 92103 (US). (74) Agents: DUFT, Bradford, J. et al.; Lyon & Lyon LLP, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE		
(57) Abstract Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that effect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF EXENDINS AND AGONISTS THEREOF
FOR THE REDUCTION OF FOOD INTAKE

This application claims the benefit of U.S.
5 Provisional Application No. 60/034,905, filed January 7,
1997, U.S. Provisional Application No. 60/055,404, filed
August 8, 1997, U.S. Provisional Application No.
60/066,029 filed November 14, 1997, and U.S. Provisional
Application No. 60/065,442, November 14, 1997.

10

FIELD OF THE INVENTION

The present invention relates to methods for treating
conditions or disorders which can be alleviated by
reducing food intake comprising administration of an
15 effective amount of an exendin or an exendin agonist alone
or in conjunction with other compounds or compositions
that affect satiety such as a leptin or an amylin agonist.
The methods are useful for treating conditions or
disorders, in which the reduction of food intake is of
20 value, including obesity, Type II diabetes, eating
disorders, and insulin-resistance syndrome. The methods
are also useful for lowering the plasma lipid level,
reducing the cardiac risk, reducing the appetite, and
reducing the weight of subjects. Pharmaceutical
25 compositions for use in the methods of the invention are
also disclosed.

BACKGROUND

The following description summarizes information relevant to the present invention. It is not an admission that any of the information provided herein is prior art to the presently claimed invention, nor that any of the publications specifically or implicitly referenced are prior art to that invention.

Exendin

Exendins are peptides that are found in the venom of the Gila-monster, a lizard found in Arizona, and the Mexican Beaded Lizard. Exendin-3 is present in the venom of Heloderma horridum, and exendin-4 is present in the venom of Heloderma suspectum (Eng, J., et al., J. Biol. Chem., 265:20259-62, 1990; Eng, J., et al., J. Biol. Chem., 267:7402-05, 1992). The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36]NH₂ (Goke, et al., J. Biol. Chem., 268:19650-55, 1993). GLP-1[7-36]NH₂, also known as proglucagon[78-107], has an insulinotropic effect, stimulating insulin secretion from pancreatic β -cells; GLP also inhibits glucagon secretion from pancreatic α -cells (Orskov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al., J. Clin. Invest., 97:133-38, 1996). GLP-1 is reported to inhibit gastric emptying (Williams B, et al., J Clin Endocrinol Metab 81 (1): 327-32, 1996; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993), and gastric acid

secretion. (Schjoldager BT, et al., Diag Dis Sci 34 (5): 703-8, 1989; O'Halloran DJ, et al., J Endocrinol 126 (1): 169-73, 1990; Wettergren A, et al., Diag Dis Sci 38 (4): 665-73, 1993). GLP-1[7-37], which has an additional glycine residue at its carboxy terminus, also stimulates insulin secretion in humans (Orskov, et al., Diabetes, 42:658-61, 1993). A transmembrane G-protein adenylate-cyclase-coupled receptor believed to be responsible for the insulinotropic effect of GLP-1 is reported to have been cloned from a β -cell line (Thorens, Proc. Natl. Acad. Sci. USA 89:8641-45 (1992)).

Exendin-4 potently binds at GLP-1 receptors on insulin-secreting β TC1 cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also said to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Goke, et al., J. Biol. Chem. 268:19650-55, 1993; Schepp, et al., Eur. J. Pharmacol., 69:183-91, 1994; Eissele, et al., Life Sci., 55:629-34, 1994).

Exendin-3 and exendin-4 were reported to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra, R., et al., Regulatory Peptides, 41:149-56, 1992; Raufman, et al., J. Biol. Chem. 267:21432-37, 1992; Singh, et al., Regul. Pept. 53:47-59, 1994). The use of exendin-3 and exendin-4 as insulinotrophic agents for the treatment of diabetes mellitus and the prevention of hyperglycemia has been proposed (Eng, U.S. Patent No. 5,424,286).

C-terminally truncated exendin peptides such as exendin[9-39], a carboxyamidated molecule, and fragments 3-39 through 9-39 have been reported to be potent and selective antagonists of GLP-1 (Goke, et al., J. Biol. Chem., 268:19650-55, 1993; Raufman, J.P., et al., J. Biol. Chem. 266:2897-902, 1991; Schepp, W., et al., Eur. J. Pharm. 269:183-91, 1994; Montrose-Rafizadeh, et al., Diabetes, 45(Suppl. 2):152A, 1996). Exendin[9-39] is said to block endogenous GLP-1 in vivo, resulting in reduced insulin secretion. Wang, et al., J. Clin. Invest., 95:417-21, 1995; D'Alessio, et al., J. Clin. Invest., 97:133-38, 1996). The receptor apparently responsible for the insulintropic effect of GLP-1 has reportedly been cloned from rat pancreatic islet cell (Thorens, B., Proc. Natl. Acad. Sci. USA 89:8641-8645, 1992). Exendins and exendin[9-39] are said to bind to the cloned GLP-1 receptor (rat pancreatic β -cell GLP-1 receptor (Fehmann HC, et al., Peptides 15 (3): 453-6, 1994) and human GLP-1 receptor (Thorens B, et al., Diabetes 42 (11): 1678-82, 1993). In cells transfected with the cloned GLP-1 receptor, exendin-4 is reportedly an agonist, i.e., it increases cAMP, while exendin[9-39] is identified as an antagonist, i.e., it blocks the stimulatory actions of exendin-4 and GLP-1. Id.

Exendin[9-39] is also reported to act as an antagonist of the full length exendins, inhibiting stimulation of pancreatic acinar cells by exendin-3 and exendin-4 (Raufman, et al., J. Biol. Chem. 266:2897-902,

1991; Raufman, et al., J. Biol. Chem., 266:21432-37, 1992). It is also reported that exendin[9-39] inhibits the stimulation of plasma insulin levels by exendin-4, and inhibits the somatostatin release-stimulating and gastrin release-inhibiting activities of exendin-4 and GLP-1 (Kolligs, F., et al., Diabetes, 44:16-19, 1995; Eissele, et al., Life Sciences, 55:629-34, 1994).

Exendins have recently been found to inhibit gastric emptying (U.S.S.N. 08/694,954, filed August 8, 1996, which enjoys common ownership with the present invention and is hereby incorporated by reference).

Exendin [9-39] has been used to investigate the physiological relevance of central GLP-1 in control of food intake (Turton, M.D. et al. Nature 379:69-72, 1996). GLP-1 administered by intracerebroventricular injection inhibits food intake in rats. This satiety-inducing effect of GLP-1 delivered ICV is reported to be inhibited by ICV injection of exendin [9-39] (Turton, supra). However, it has been reported that GLP-1 does not inhibit food intake in mice when administered by peripheral injection (Turton, M.D., Nature 379:69-72, 1996; Bhavsar, S.P., Soc. Neurosci. Abstr. 21:460 (188.8), 1995).

Obesity and Hypernutrition

Obesity, excess adipose tissue, is becoming increasingly prevalent in developed societies. For example, approximately 30% of adults in the U.S. were estimated to be 20 percent above desirable body weight -- an accepted measure of obesity sufficient to impact a health risk (Harrison's *Principles of Internal Medicine*

12th Edition, McGraw Hill, Inc. (1991) p. 411). The pathogenesis of obesity is believed to be multifactorial but the basic problem is that in obese subjects food intake and energy expenditure do not come into balance until there is excess adipose tissue. Attempts to reduce food intake, or hypernutrition, are usually fruitless in the medium term because the weight loss induced by dieting results in both increased appetite and decreased energy expenditure (Leibel et al., (1995) *New England Journal of Medicine* 322: 621-628). The intensity of physical exercise required to expend enough energy to materially lose adipose mass is too great for most people to undertake on a sufficiently frequent basis. Thus, obesity is currently a poorly treatable, chronic, essentially intractable metabolic disorder. Not only is obesity itself believed by some to be undesirable for cosmetic reasons, but obesity also carries serious risk of comorbidities including, Type 2 diabetes, increased cardiac risk, hypertension, atherosclerosis, degenerative arthritis, and increased incidence of complications of surgery involving general anesthesia. Obesity due to hypernutrition is also a risk factor for the group of conditions called insulin resistance syndrome, or "syndrome X." In syndrome X, it has been reported that there is a linkage between insulin resistance and hypertension. (Watson N. and Sandler M., *Curr. Med. Res. Opin.*, 12(6):374-378 (1991); Kodama J. et al., *Diabetes Care*, 13(11):1109-1111 (1990); Lithell et al., *J. Cardiovasc. Pharmacol.*, 15 Suppl. 5:S46-S52 (1990)).

In those few subjects who do succeed in losing weight, by about 10 percent of body weight, there can be striking improvements in co-morbid conditions, most especially Type 2 diabetes in which dieting and weight loss are the primary therapeutic modality, albeit relatively ineffective in many patients for the reasons stated above. Reducing food intake in obese subjects would decrease the plasma glucose level, the plasma lipid level, and the cardiac risk in these subjects.

Hypernutrition is also the result of, and the psychological cause of, many eating disorders. Reducing food intake would also be beneficial in the treatment of such disorders.

Thus, it can be appreciated that an effective means to reduce food intake is a major challenge and a superior method of treatment would be of great utility. Such a method, and compounds and compositions which are useful therefor, have been invented and are described and claimed herein.

SUMMARY OF THE INVENTION

The present invention concerns the surprising discovery that exendins and exendin agonists have a profound and prolonged effect on inhibiting food intake.

The present invention is directed to novel methods for treating conditions or disorders associated with hypernutrition, comprising the administration of an exendin, for example, exendin-3 [SEQ ID NO. 1: His Ser Asp

Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu
Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser Ser Gly Ala Pro Pro Pro Ser], or exendin-4 [SEQ ID NO.
2: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or other
compounds which effectively bind to the receptor at which
exendin exerts its action on reducing food intake. These
methods will be useful in the treatment of, for example,
10 obesity, diabetes, including Type II or non-insulin
dependent diabetes, eating disorders, and insulin-
resistance syndrome.

In a first aspect, the invention features a method of
treating conditions or disorders which can be alleviated
15 by reducing food intake in a subject comprising
administering to the subject a therapeutically effective
amount of an exendin or an exendin agonist. By an "exendin
agonist" is meant a compound that mimics the effects of
exendin on the reduction of food intake by binding to the
20 receptor or receptors where exendin causes this effect.
Preferred exendin agonist compounds include those described
in United States Provisional Patent Application Serial No.
60/055,404, entitled, "Novel Exendin Agonist Compounds,"
filed August 8, 1997; United States Provisional Patent
25 Application Serial No. 60/065,442, entitled, "Novel Exendin
Agonist Compounds," filed November 14, 1997; and United
States Provisional Patent Application Serial No.
60/066,029, entitled, "Novel Exendin Agonist Compounds,"
filed November 14, 1997; all of which enjoy common

ownership with the present application and all of which are incorporated by this reference into the present application as though fully set forth herein. By "condition or disorder which can be alleviated by reducing food intake" is meant any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high food intake, or that can be alleviated by reducing food intake. Such conditions or disorders include, but are not limited to, obesity, diabetes, including Type II diabetes, eating disorders, and insulin-resistance syndrome.

Thus, in a first embodiment, the present invention provides a method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Serial Nos. 60/055,404; 60/065,442; and 60/066,029, which have been incorporated by reference in the present application. Preferably, the subject is a vertebrate, more preferably a mammal, and most preferably a human. In preferred aspects, the exendin or exendin agonist is administered parenterally, more preferably by injection. In a most preferred aspect, the injection is a peripheral injection. Preferably, about 10 μ g-30 μ g to about 5 mg of the exendin or exendin agonist is administered per day. More preferably, about 10-30 μ g to about 2mg, or about 10-30 μ g to about 1mg of the exendin or

exendin agonist is administered per day. Most preferably, about 30 μ g to about 500 μ g of the exendin or exendin agonist is administered per day.

5 In various preferred embodiments of the invention, the condition or disorder is obesity, diabetes, preferably Type II diabetes, an eating disorder, or insulin-resistance syndrome.

10 In other preferred aspects of the invention, a method is provided for reducing the appetite of a subject comprising administering to said subject an appetite-lowering amount of an exendin or an exendin agonist.

15 In yet other preferred aspects, a method is provided for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

20 The methods of the present invention may also be used to reduce the cardiac risk of a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. In one preferred aspect, the exendin or exendin agonist used in the methods of the present invention is exendin-3. In another preferred aspect, said exendin is exendin-4. Other preferred exendin agonists include exendin-4 (1-30) [SEQ ID NO 6: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
25 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly], exendin-4 (1-30) amide [SEQ ID NO 7: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH₂], exendin-4 (1-28) amide [SEQ ID NO 40: His Gly Glu Gly Thr

Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg
 Leu Phe Ile Glu Trp Leu Lys Asn-NH₂], ¹⁴Leu, ²⁵Phe exendin-4
 amide [SEQ ID NO 9: His Gly Glu Gly Thr Phe Thr Ser Asp Leu
 Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe
 5 Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-
 NH₂], ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide [SEQ ID NO 41: His
 Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu
 Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂], and
¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide [SEQ ID NO 8: His Gly
 10 Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu
 Ala Val Arg Leu Ala Ile Glu Phe Leu Lys Asn-NH₂].

In the methods of the present invention, the exendins
 and exendin agonists may be administered separately or
 together with one or more other compounds and compositions
 15 that exhibit a long term or short-term satiety action,
 including, but not limited to other compounds and
 compositions that comprise an amylin agonist,
 cholecystokinin (CCK), or a leptin (ob protein). Suitable
 amylin agonists include, for example, [^{25,28,29}Pro-]-human
 20 amylin (also known as "pramlintide," and previously
 referred to as "AC-137") as described in "Amylin Agonist
 Peptides and Uses Therefor," U.S. Patent No. 5,686,511,
 issued November 11, 1997, and salmon calcitonin. The CCK
 used is preferably CCK octopeptide (CCK-8). Leptin is
 25 discussed in, for example, Pelleymounter, M.A., et al.
Science 269:540-43 (1995); Halaas, J.L., et al. Science
 269:543-46 (1995); and Campfield, L.A., et al. Eur. J.
Pharmac. 262:133-41 (1994).

In other embodiments of the invention is provided a pharmaceutical composition for use in the treatment of conditions or disorders which can be alleviated by reducing food intake comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition comprises a therapeutically effective amount for a human subject.

The pharmaceutical composition may preferably be used for reducing the appetite of a subject, reducing the weight of a subject, lowering the plasma lipid level of a subject, or reducing the cardiac risk of a subject. Those of skill in the art will recognize that the pharmaceutical composition will preferably comprise a therapeutically effective amount of an exendin or exendin agonist to accomplish the desired effect in the subject.

The pharmaceutical compositions may further comprise one or more other compounds and compositions that exhibit a long-term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, CCK, preferably CCK-8, or leptin. Suitable amylin agonists include, for example, [^{25,28,29}Pro]-human amylin and salmon calcitonin.

In one preferred aspect, the pharmaceutical composition comprises exendin-3. In another preferred aspect, the pharmaceutical composition comprises exendin-4.

In other preferred aspects, the pharmaceutical compositions comprises a peptide selected from: exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide,

¹⁴Leu, ²⁵Phe exendin-4 amide, ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 and GLP-1.

10

Figure 2 is a graphical depiction of the change of food intake in obese mice after intraperitoneal injection of exendin-4.

Figure 3 is a graphical depiction of the change of food intake in rats after intracerebroventricular injection of exendin-4

15

Figure 4 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) ("Compound 1").

20

Figure 5 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) amide ("Compound 2").

Figure 6 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-28) amide ("Compound 3").

25

Figure 7 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of ¹⁴Leu, ²⁵Phe exendin-4 amide ("Compound 4").

Figure 8 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide ("Compound 5").

Figure 9 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of ¹⁴Leu, ²³Ala, ²⁵Phe exendin-4 (1-28) amide ("Compound 6").

Figure 10 depicts the amino acid sequences for certain exendin agonist compounds useful in the present invention [SEQ ID NOS 9-39].

DETAILED DESCRIPTION OF THE INVENTION

Exendins and exendin agonists are useful as described herein in view of their pharmacological properties. Activity as exendin agonists can be indicated by activity in the assays described below. Effects of exendins or exendin agonists on reducing food intake can be identified, evaluated, or screened for, using the methods described in the Examples below, or other methods known in the art for determining effects on food intake or appetite.

Exendin Agonist Compounds

Exendin agonist compounds are those described in U.S. Provisional Application No. 60/055,404, including compounds of the formula (I) [SEQ ID NO. 3]:

25	1	5	10
	Xaa ₁	Xaa ₂	Xaa ₃
		Gly	Thr
			Xaa ₄
			Xaa ₅
			Xaa ₆
			Xaa ₇
			Xaa ₈
			Xaa ₉
			Xaa ₁₀
			Xaa ₁₁
			Xaa ₁₂
			Xaa ₁₃
			Xaa ₁₄
			Xaa ₁₅
			Xaa ₁₆
			Xaa ₁₇
			Xaa ₁₈
			Xaa ₁₉
			Xaa ₂₀
			Xaa ₂₁
			Xaa ₂₂
			Xaa ₂₃
			Xaa ₂₄
			Xaa ₂₅
			Xaa ₂₆
			Xaa ₂₇
			Xaa ₂₈
			Xaa ₂₉
			Xaa ₃₀
			Xaa ₃₁
			Xaa ₃₂
			Xaa ₃₃
			Xaa ₃₄
			Xaa ₃₅
			Xaa ₃₆
			Xaa ₃₇
			Xaa ₃₈
			Xaa ₃₉
			Xaa ₄₀
			Xaa ₄₁
			Xaa ₄₂
			Xaa ₄₃
			Xaa ₄₄
			Xaa ₄₅
			Xaa ₄₆
			Xaa ₄₇
			Xaa ₄₈
			Xaa ₄₉
			Xaa ₅₀
			Xaa ₅₁
			Xaa ₅₂
			Xaa ₅₃
			Xaa ₅₄
			Xaa ₅₅
			Xaa ₅₆
			Xaa ₅₇
			Xaa ₅₈
			Xaa ₅₉
			Xaa ₆₀
			Xaa ₆₁
			Xaa ₆₂
			Xaa ₆₃
			Xaa ₆₄
			Xaa ₆₅
			Xaa ₆₆
			Xaa ₆₇
			Xaa ₆₈
			Xaa ₆₉
			Xaa ₇₀
			Xaa ₇₁
			Xaa ₇₂
			Xaa ₇₃
			Xaa ₇₄
			Xaa ₇₅
			Xaa ₇₆
			Xaa ₇₇
			Xaa ₇₈
			Xaa ₇₉
			Xaa ₈₀
			Xaa ₈₁
			Xaa ₈₂
			Xaa ₈₃
			Xaa ₈₄
			Xaa ₈₅
			Xaa ₈₆
			Xaa ₈₇
			Xaa ₈₈
			Xaa ₈₉
			Xaa ₉₀
			Xaa ₉₁
			Xaa ₉₂
			Xaa ₉₃
			Xaa ₉₄
			Xaa ₉₅
			Xaa ₉₆
			Xaa ₉₇
			Xaa ₉₈
			Xaa ₉₉
			Xaa ₁₀₀
			Xaa ₁₀₁
			Xaa ₁₀₂
			Xaa ₁₀₃
			Xaa ₁₀₄
			Xaa ₁₀₅
			Xaa ₁₀₆
			Xaa ₁₀₇
			Xaa ₁₀₈
			Xaa ₁₀₉
			Xaa ₁₁₀
			Xaa ₁₁₁
			Xaa ₁₁₂
			Xaa ₁₁₃
			Xaa ₁₁₄
			Xaa ₁₁₅
			Xaa ₁₁₆
			Xaa ₁₁₇
			Xaa ₁₁₈
			Xaa ₁₁₉
			Xaa ₁₂₀
			Xaa ₁₂₁
			Xaa ₁₂₂
			Xaa ₁₂₃
			Xaa ₁₂₄
			Xaa ₁₂₅
			Xaa ₁₂₆
			Xaa ₁₂₇
			Xaa ₁₂₈
			Xaa ₁₂₉
			Xaa ₁₃₀
			Xaa ₁₃₁
			Xaa ₁₃₂
			Xaa ₁₃₃
			Xaa ₁₃₄
			Xaa ₁₃₅
			Xaa ₁₃₆
			Xaa ₁₃₇
			Xaa ₁₃₈
			Xaa ₁₃₉
			Xaa ₁₄₀
			Xaa ₁₄₁
			Xaa ₁₄₂
			Xaa ₁₄₃
			Xaa ₁₄₄
			Xaa ₁₄₅
			Xaa ₁₄₆
			Xaa ₁₄₇
			Xaa ₁₄₈
			Xaa ₁₄₉
			Xaa ₁₅₀
			Xaa ₁₅₁
			Xaa ₁₅₂
			Xaa ₁₅₃
			Xaa ₁₅₄
			Xaa ₁₅₅
			Xaa ₁₅₆
			Xaa ₁₅₇
			Xaa ₁₅₈
			Xaa ₁₅₉
			Xaa ₁₆₀
			Xaa ₁₆₁
			Xaa ₁₆₂
			Xaa ₁₆₃
			Xaa ₁₆₄
			Xaa ₁₆₅
			Xaa ₁₆₆
			Xaa ₁₆₇
			Xaa ₁₆₈
			Xaa ₁₆₉
			Xaa ₁₇₀
			Xaa ₁₇₁
			Xaa ₁₇₂
			Xaa ₁₇₃
			Xaa ₁₇₄
			Xaa ₁₇₅
			Xaa ₁₇₆
			Xaa ₁₇₇
			Xaa ₁₇₈
			Xaa ₁₇₉
			Xaa ₁₈₀
			Xaa ₁₈₁
			Xaa ₁₈₂
			Xaa ₁₈₃
			Xaa ₁₈₄
			Xaa ₁₈₅
			Xaa ₁₈₆
			Xaa ₁₈₇
			Xaa ₁₈₈
			Xaa ₁₈₉
			Xaa ₁₉₀
			Xaa ₁₉₁
			Xaa ₁₉₂
			Xaa ₁₉₃
			Xaa ₁₉₄
			Xaa ₁₉₅
			Xaa ₁₉₆
			Xaa ₁₉₇
			Xaa ₁₉₈
			Xaa ₁₉₉
			Xaa ₂₀₀
			Xaa ₂₀₁
			Xaa ₂₀₂
			Xaa ₂₀₃
			Xaa ₂₀₄
			Xaa ₂₀₅
			Xaa ₂₀₆
			Xaa ₂₀₇
			Xaa ₂₀₈
			Xaa ₂₀₉
			Xaa ₂₁₀
			Xaa ₂₁₁
			Xaa ₂₁₂
			Xaa ₂₁₃
			Xaa ₂₁₄
			Xaa ₂₁₅
			Xaa ₂₁₆
			Xaa ₂₁₇
			Xaa ₂₁₈
			Xaa ₂₁₉
			Xaa ₂₂₀
			Xaa ₂₂₁
			Xaa ₂₂₂
			Xaa ₂₂₃
			Xaa ₂₂₄
			Xaa ₂₂₅
			Xaa ₂₂₆
			Xaa ₂₂₇
			Xaa ₂₂₈
			Xaa ₂₂₉
			Xaa ₂₃₀
			Xaa ₂₃₁
			Xaa ₂₃₂
			Xaa ₂₃₃
			Xaa ₂₃₄
			Xaa ₂₃₅
			Xaa ₂₃₆
			Xaa ₂₃₇
			Xaa ₂₃₈
			Xaa ₂₃₉
			Xaa ₂₄₀
			Xaa ₂₄₁
			Xaa ₂₄₂
			Xaa ₂₄₃
			Xaa ₂₄₄
			Xaa ₂₄₅
			Xaa ₂₄₆
			Xaa ₂₄₇
			Xaa ₂₄₈
			Xaa ₂₄₉
			Xaa ₂₅₀
			Xaa ₂₅₁
			Xaa ₂₅₂
			Xaa ₂₅₃
			Xaa ₂₅₄
			Xaa ₂₅₅
			Xaa ₂₅₆
			Xaa ₂₅₇
			Xaa ₂₅₈
			Xaa ₂₅₉
			Xaa ₂₆₀
			Xaa ₂₆₁
			Xaa ₂₆₂
			Xaa ₂₆₃
			Xaa ₂₆₄
			Xaa ₂₆₅
			Xaa ₂₆₆
			Xaa ₂₆₇
			Xaa ₂₆₈
			Xaa ₂₆₉
			Xaa ₂₇₀
			Xaa ₂₇₁
			Xaa ₂₇₂
			Xaa ₂₇₃
			Xaa ₂₇₄
			Xaa ₂₇₅
			Xaa ₂₇₆
			Xaa ₂₇₇
			Xaa ₂₇₈
			Xaa ₂₇₉
			Xaa ₂₈₀
			Xaa ₂₈₁
			Xaa ₂₈₂
			Xaa ₂₈₃
			Xaa ₂₈₄
			Xaa ₂₈₅
			Xaa ₂₈₆
			Xaa ₂₈₇
			Xaa ₂₈₈
			Xaa ₂₈₉
			Xaa ₂₉₀
			Xaa ₂₉₁
			Xaa ₂₉₂
			Xaa ₂₉₃
			Xaa ₂₉₄
			Xaa ₂₉₅
			Xaa ₂₉₆
			Xaa ₂₉₇
			Xaa ₂₉₈
			Xaa ₂₉₉
			Xaa ₃₀₀
			Xaa ₃₀₁
			Xaa ₃₀₂
			Xaa ₃₀₃
			Xaa ₃₀₄
			Xaa ₃₀₅
			Xaa ₃₀₆
			Xaa ₃₀₇
			Xaa ₃₀₈
			Xaa ₃₀₉
			Xaa ₃₁₀
			Xaa ₃₁₁
			Xaa ₃₁₂
			Xaa ₃₁₃
			Xaa ₃₁₄
			Xaa ₃₁₅
			Xaa ₃₁₆
			Xaa ₃₁₇
			Xaa ₃₁₈
			Xaa ₃₁₉
			Xaa ₃₂₀
			Xaa ₃₂₁ </

wherein Xaa₁ is His, Arg or Tyr; Xaa₂ is Ser, Gly, Ala or Thr; Xaa₃ is Asp or Glu; Xaa₄ is Phe, Tyr or naphthylalanine; Xaa₅ is Thr or Ser; Xaa₆ is Ser or Thr; Xaa₇ is Asp or Glu; Xaa₈ is Leu, Ile, Val, pentylglycine or Met; Xaa₉ is Leu, Ile, pentylglycine, Val or Met; Xaa₁₀ is Phe, Tyr or naphthylalanine; Xaa₁₁ is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa₁₂ is Glu or Asp; Xaa₁₃ is Trp, Phe, Tyr, or naphthylalanine; Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa₁₈ is Ser, Thr or Tyr; and Z is -OH or -NH₂; with the proviso that the compound is not exendin-3 or exindin-4.

Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds include those listed in Figure 10 having amino acid sequences of SEQ. ID. NOS. 9 to 39.

Preferred exendin agonist compounds include those wherein Xaa₁ is His or Tyr. More preferably Xaa₁ is His.

Preferred are those compounds wherein Xaa₂ is Gly.

Preferred are those compounds wherein Xaa₃ is Leu, pentylglycine or Met.

Preferred compounds include those wherein Xaa₁₃ is Trp or Phe.

Also preferred are compounds where Xaa₄ is Phe or naphthylalanine; Xaa₁₁ is Ile or Val and Xaa₁₄, Xaa₁₅, Xaa₁₆

and Xaa₁₇ are independently selected from Pro, homoproline, thioproline or N-alkylalanine. Preferably N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.

According to an especially preferred aspect, Xaa₁₅,
5 Xaa₁₆ and Xaa₁₇ are the same amino acid residue.

Preferred are compounds wherein Xaa₁₈ is Ser or Tyr, more preferably Ser.

Preferably Z is -NH₂.

According to one aspect, preferred are compounds of
10 formula (I) wherein Xaa₁ is His or Tyr, more preferably His; Xaa₂ is Gly; Xaa₃ is Phe or naphthylalanine; Xaa₄ is Leu, pentylglycine or Met; Xaa₁₀ is Phe or naphthylalanine; Xaa₁₁ is Ile or Val; Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are
independently selected from Pro, homoproline, thioproline
15 or N-alkylalanine; and Xaa₁₈ is Ser or Tyr, more preferably Ser. More preferably Z is -NH₂.

According to an especially preferred aspect,
especially preferred compounds include those of formula
(I) wherein: Xaa₁ is His or Arg; Xaa₂ is Gly; Xaa₃ is Asp
20 or Glu; Xaa₄ is Phe or naphthylalanine; Xaa₅ is Thr or Ser;

Xaa₆ is Ser or Thr; Xaa₇ is Asp or Glu; Xaa₈ is Leu or pentylglycine; Xaa₉ is Leu or pentylglycine; Xaa₁₀ is Phe or naphthylalanine; Xaa₁₁ is Ile, Val or t-butyltylglycine; Xaa₁₂ is Glu or Asp; Xaa₁₃ is Trp or Phe; Xaa₁₄, Xaa₁₅, Xaa₁₆,
25 and Xaa₁₇ are independently Pro, homoproline, thioproline, or N-methylalanine; Xaa₁₈ is Ser or Tyr; and Z is -OH or -NH₂; with the proviso that the compound does not have the formula of either SEQ. ID. NOS. 1 or 2. More preferably Z

is -NH₂. Especially preferred compounds include those having the amino acid sequence of SEQ. ID. NOS. 9, 10, 21, 22, 23, 26, 28, 34, 35 and 39.

5 According to an especially preferred aspect, provided are compounds where Xaa₁ is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa₁₃ is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will exhibit advantageous
10 duration of action and be less subject to oxidative degradation, both in vitro and in vivo, as well as during synthesis of the compound.

 Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442,
15 including compounds of the formula (II) [SEQ ID NO. 4]:

Xaa₁, Xaa₂, Xaa₃, Gly Xaa₄, Xaa₅, Xaa₆, Xaa₇, Xaa₈, Xaa₉, Xaa₁₀,
Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Ala Xaa₁₉, Xaa₂₀,
Xaa₂₁, Xaa₂₂, Xaa₂₃, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇, Xaa₂₈-Z₁; wherein

20

Xaa₁ is His, Arg or Tyr;

Xaa₂ is Ser, Gly, Ala or Thr;

Xaa₃ is Asp or Glu;

Xaa₄ is Ala or Thr;

25 Xaa₅ is Ala, Phe, Tyr or naphthylalanine;

Xaa₆ is Thr or Ser;

Xaa₇ is Ala, Ser or Thr;

Xaa₈ is Asp or Glu;

- Xaa₁₀ is Ala, Leu, Ile, Val, pentylglycine or Met;
 Xaa₁₁ is Ala or Ser;
 Xaa₁₂ is Ala or Lys;
 Xaa₁₃ is Ala or Gln;
- 5 Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;
 Xaa₁₅ is Ala or Glu;
 Xaa₁₆ is Ala or Glu;
 Xaa₁₇ is Ala or Glu;
 Xaa₁₉ is Ala or Val;
- 10 Xaa₂₀ is Ala or Arg;
 Xaa₂₁ is Ala or Leu;
 Xaa₂₂ is Ala, Phe, Tyr or naphthylalanine;
 Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine
 or Met;
- 15 Xaa₂₄ is Ala, Glu or Asp;
 Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine;
 Xaa₂₆ is Ala or Leu;
 Xaa₂₇ is Ala or Lys;
 Xaa₂₈ is Ala or Asn;
- 20 Z₁ is-OH,
 -NH₂
 Gly-Z₂,
 Gly Gly-Z₂,
 Gly Gly Xaa₃₁-Z₂,
 Gly Gly Xaa₃₁ Ser-Z₂,
 Gly Gly Xaa₃₁ Ser Ser-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,
- 25

- Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂,
Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂ or
Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂;
Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ are independently Pro,
5 homoproline, 3Hyp, 4Hyp, thioproline,
N-alkylglycine, N-alkylpentylglycine or
N-alkylalanine; and
Z₂ is -OH or -NH₂;
provided that no more than three of Xaa₃, Xaa₅, Xaa₆, Xaa₈,
10 Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Xaa₁₉,
Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈ are Ala.
Preferred N-alkyl groups for N-alkylglycine, N-
alkylpentylglycine and N-alkylalanine include lower alkyl
groups preferably of 1 to about 6 carbon atoms, more
15 preferably of 1 to 4 carbon atoms.
Preferred exendin agonist compounds include those
wherein Xaa₁ is His or Tyr. More preferably Xaa₁ is His.
Preferred are those compounds wherein Xaa₂ is Gly.
Preferred are those compounds wherein Xaa₄ is Leu,
20 pentylglycine or Met.
Preferred compounds are those wherein Xaa₂₅ is Trp or
Phe.
Preferred compounds are those where Xaa₆ is Phe or
naphthylalanine; Xaa₂₂ is Phe or naphthylalanine and
25 Xaa₂₃ is Ile or Val.
Preferred are compounds wherein Xaa₃₁, Xaa₃₆, Xaa₃₇ and
Xaa₃₈ are independently selected from Pro, homoproline,
thioproline and N-alkylalanine.

Preferably Z_1 is $-NH_2$.

Preferable Z_2 is $-NH_2$.

According to one aspect, preferred are compounds of formula (I) wherein Xaa_1 is His or Tyr, more preferably His; Xaa_2 is Gly; Xaa_3 is Phe or naphthylalanine; Xaa_4 is Leu, pentylglycine or Met; Xaa_{22} is Phe or naphthylalanine; Xaa_{23} is Ile or Val; Xaa_{31} , Xaa_{36} , Xaa_{37} and Xaa_{38} are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z_1 is $-NH_2$.

According to an especially preferred aspect, especially preferred compounds include those of formula (I) wherein: Xaa_1 is His or Arg; Xaa_2 is Gly or Ala; Xaa_3 is Asp or Glu; Xaa_4 is Ala or Thr; Xaa_5 is Ala, Phe or naphthylalanine; Xaa_6 is Thr or Ser; Xaa_8 is Ala, Ser or Thr; Xaa_9 is Asp or Glu; Xaa_{10} is Ala, Leu or pentylglycine; Xaa_{11} is Ala or Ser; Xaa_{12} is Ala or Lys; Xaa_{13} is Ala or Gln; Xaa_{14} is Ala, Leu or pentylglycine; Xaa_{15} is Ala or Glu; Xaa_{16} is Ala or Glu; Xaa_{17} is Ala or Glu; Xaa_{19} is Ala or Val; Xaa_{20} is Ala or Arg; Xaa_{21} is Ala or Leu; Xaa_{22} is Phe or naphthylalanine; Xaa_{23} is Ile, Val or tert-butylglycine; Xaa_{24} is Ala, Glu or Asp; Xaa_{25} is Ala, Trp or Phe; Xaa_{26} is Ala or Leu; Xaa_{27} is Ala or Lys; Xaa_{28} is Ala or Asn; Z_1 is $-OH$, $-NH_2$, Gly- Z_2 , Gly Gly- Z_2 , Gly Gly Xaa_{31} - Z_2 , Gly Gly Xaa_{31} Ser- Z_2 , Gly Gly Xaa_{31} Ser Ser- Z_2 , Gly Gly Xaa_{31} Ser Ser Gly- Z_2 , Gly Gly Xaa_{31} Ser Ser Gly Ala- Z_2 , Gly Gly Xaa_{31} Ser Ser Gly Ala Xaa_{36} - Z_2 , Gly Gly Xaa_{31} Ser Ser Gly Ala Xaa_{36} Xaa_{37} - Z_2 , Gly Gly Xaa_{31} Ser Ser Gly Ala Xaa_{36} Xaa_{37} Xaa_{38} - Z_2 ; Xaa_{31} , Xaa_{36} , Xaa_{37} and Xaa_{38} being independently Pro homoproline, thioproline or N-

methyllalanine; and Z₂ being -OH or -NH₂; provided that no more than three of Xaa₃, Xaa₅, Xaa₆, Xaa₈, Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Xaa₁₉, Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈ are Ala. Especially
 5 preferred compounds include those having the amino acid sequence of SEQ. ID. NOS. 40-61.

According to an especially preferred aspect, provided are compounds where Xaa₁₄ is Leu, Ile, Val or pentyglycine, more preferably Leu or pentyglycine, and
 10 Xaa₂₅ is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will be less susceptible to oxidative degradation, both in vitro and in vivo, as well as during synthesis of the compound.

Exendin agonist compounds also include those
 15 described in U.S. Provisional Application No. 60/066,029, including compounds of the formula (III) [SEQ ID NO. 5]:

Xaa₁, Xaa₂, Xaa₃, Xaa₄, Xaa₅, Xaa₆, Xaa₇, Xaa₈, Xaa₉, Xaa₁₀
 Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Ala, Xaa₁₉, Xaa₂₀
 20 Xaa₂₁, Xaa₂₂, Xaa₂₃, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇, Xaa₂₈-Z₁; wherein

Xaa₁ is His, Arg, Tyr, Ala, Norval, Val or Norleu;

Xaa₂ is Ser, Gly, Ala or Thr;

25 Xaa₃ is Ala, Asp or Glu;

Xaa₄ is Ala, Norval, Val, Norleu or Gly;

Xaa₅ is Ala or Thr;

Xaa₆ is Phe, Tyr or naphthylalanine;

- Xaa₁ is Thr or Ser;
- Xaa₂ is Ala, Ser or Thr;
- Xaa₃ is Ala, Norval, Val, Norleu, Asp or Glu;
- Xaa₁₀ is Ala, Leu, Ile, Val, pentylglycine or Met;
- 5 Xaa₁₁ is Ala or Ser;
- Xaa₁₂ is Ala or Lys;
- Xaa₁₃ is Ala or Gln;
- Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;
- Xaa₁₅ is Ala or Glu;
- 10 Xaa₁₆ is Ala or Glu;
- Xaa₁₇ is Ala or Glu;
- Xaa₁₉ is Ala or Val;
- Xaa₂₀ is Ala or Arg;
- Xaa₂₁ is Ala or Leu;
- 15 Xaa₂₂ is Phe, Tyr or naphthylalanine;
- Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
- Xaa₂₄ is Ala, Glu or Asp;
- Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine;
- 20 Xaa₂₆ is Ala or Leu;
- Xaa₂₇ is Ala or Lys;
- Xaa₂₈ is Ala or Asn;
- Z₁ is -OH,
- NH₂,
- 25 Gly-Z₂,
- Gly Gly-Z₂,
- Gly Gly Xaa₃₁-Z₂,
- Gly Gly Xaa₃₁ Ser-Z₂,

Gly Gly Xaa₃₁ Ser Ser-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂,
 5 Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂,
 Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂ or Gly
 Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈ Xaa₃₉-Z₂; wherein
 Xaa₃₁, Xaa₃₆, Xaa₃₇, and Xaa₃₈ are independently
 Pro, homoproline, 3Hyp, 4Hyp, thioproline,
 10 N-alkylglycine, N-alkylpentylglycine or
 N-alkylalanine; and
 Z₂ is -OH or -NH₂;

provided that no more than three of Xaa₃, Xaa₄, Xaa₅, Xaa₆,
 Xaa₈, Xaa₉, Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆,
 15 Xaa₁₇, Xaa₁₉, Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈
 are Ala; and provided also that, if Xaa₁ is His, Arg or
 Tyr, then at least one of Xaa₃, Xaa₄, and Xaa₅ is Ala.

Definitions

20 In accordance with the present invention and as used
 herein, the following terms are defined to have the
 following meanings, unless explicitly stated otherwise.


The term "amino acid" refers to natural amino acids,
 unnatural amino acids, and amino acid analogs, all in
 25 their D and L stereoisomers if their structure allow such
 stereoisomeric forms. Natural amino acids include alanine
 (Ala), arginine (Arg), asparagine (Asn), aspartic acid
 (Asp), cysteine (Cys), glutamine (Gln), glutamic acid
 (Glu), glycine (Gly), histidine (His), isoleucine (Ile),

leucine (Leu), Lysine (Lys), methionine (Met),
phenylalanine (Phe), proline (Pro), serine (Ser),
threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and
valine (Val). Unnatural amino acids include, but are not
5 limited to azetidinecarboxylic acid, 2-aminoadipic acid,
3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-
aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic
acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-
aminoisobutyric acid, 2-aminopimelic acid, tertiary-
10 butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-
diaminopimelic acid, 2,3-diaminopropionic acid, N-
ethylglycine, N-ethylasparagine, homoproline,
hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-
hydroxyproline, isodesmosine, allo-isoleucine, N-
15 methylalanine, N-methylglycine, N-methylisoleucine, N-
methylpentylglycine, N-methylvaline, naphthalanine,
norvaline, norleucine, ornithine, pentylglycine, pipecolic
acid and thioproline. Amino acid analogs include the
natural and unnatural amino acids which are chemically
20 blocked, reversibly or irreversibly, or modified on their
N-terminal amino group or their side-chain groups, as for
example, methionine sulfoxide, methionine sulfone, S-
(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine
sulfoxide and S-(carboxymethyl)-cysteine sulfone.

25 The term "amino acid analog" refers to an amino acid
wherein either the C-terminal carboxy group, the N-
terminal amino group or side-chain functional group has
been chemically codified to another functional group. For
example, aspartic acid-(beta-methyl ester) is an amino

acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is an amino acid analog of alanine.

The term "amino acid residue" refers to radicals
 5 having the structure: (1) $-C(O)-R-NH-$, wherein R typically is $-CH(R')$ -, wherein R' is an amino acid side chain, typically H or a carbon containing substituent; or (2),



10

wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipercolic acid residues, respectively.

The term "lower" referred to herein in connection
 15 with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms. Such groups may be straight chain or branched chain.

20 "Pharmaceutically acceptable salt" includes salts of the compounds described herein derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds are useful in both free
 25 base and salt form.

In addition, the following abbreviations stand for the following:

- "ACN" or "CH₃CN" refers to acetonitrile.
- "Boc", "tBoc" or "Tboc" refers to t-butoxy carbonyl.
- 5 "DCC" refers to N,N'-dicyclohexylcarbodiimide.
- "Fmoc" refers to fluorenylmethoxycarbonyl.
- "HBTU" refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate.
- "HOBt" refers to 1-hydroxybenzotriazole monohydrate.
- 10 "homop" or hPro" refers to homoproline.
- "MeAla" or "Nme" refers to N-methylalanine.
- "naph" refers to naphthylalanine.
- "pG" or pGly" refers to pentylglycine.
- "tBuG" refers to tertiary-butylglycine.
- 15 "ThioP" or tPro" refers to thioproline.
- 3Hyp" refers to 3-hydroxyproline
- 4Hyp" refers to 4-hydroxyproline
- NAG" refers to N-alkylglycine
- NAPG" refers to N-alkylpentylglycine
- 20 "Norval" refers to norvaline
- "Norleu" refers to norleucine

Preparation of Compounds

- 25 The exendins and exendin agonists described herein may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such

techniques, an α -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or
5 methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α -N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as
10 trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl
15 (Fmoc) being preferred herein.

The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, CA). The following side-chain protected
20 amino acids may be purchased from Applied Biosystems, Inc.: Boc-Arg(Mts), Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-
25 Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, CA). Anisole, dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from

Aldrich Chemical Company (Milwaukee, WI). Air Products and Chemicals (Allentown, PA) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, PA).

5 Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, CA) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide
10 Synthesizer, Version 1.3B July 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, CA) with capping. Boc-peptide-resins may be cleaved with HF (-5° C to 0° C, 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the
15 filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville,
20 Kentucky).

Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10 μ , 2.2 x 25 cm; Vydac, Hesperia, CA) may be used to isolate peptides, and purity
25 may be determined using a C4, C8 or C18 analytical column (5 μ , 0.46 x 25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH₃CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed

on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C, 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, PA).

Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried out on a VG-Trio machine.

Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate-containing amino acids and peptides containing such amino acids, may be prepared using methods known in the art. See, e.g., Bartlett and Landen, Biorg. Chem. 14:356-377 (1986).

The compounds described above are useful in view of their pharmacological properties. In particular, the compounds of the invention possess activity as agents to reduce food intake. They can be used to treat conditions or diseases which can be alleviated by reducing food

intake.

Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. In some cases, it will be convenient to provide an exendin or exendin agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent, such as amylin, an amylin agonist, a CCK, or a leptin, in a single composition or solution for administration together. In other cases, it may be more advantageous to administer the additional agent separately from said exendin or exendin agonist. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J. and Hanson, M.A. "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).

Compounds useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to 8.0, preferably at a pH of

about 3.5 to 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.

The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.

The claimed compositions can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher

concentrations of the drug.

Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid. Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, transmucosally, or by

pulmonary inhalation.

If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose.

They may be prepared in emulsified form, either water in
5 oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a
10 Triton).

Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to
15 produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.

For use by the physician, the compositions will be
20 provided in dosage unit form containing an amount of an exendin or exendin agonist, for example, exendin-3, and/or exendin-4, with or without another food intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent. Therapeutically effective amounts of an exendin or exendin
25 agonist for use in reducing food intake are those that suppress appetite at a desired level. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical

condition, the blood sugar level and other factors.

The effective daily appetite-suppressing dose of the compounds will typically be in the range of about 10 to 30 μg to about 5 mg/day, preferably about 10 to 30 μg to about 2 mg/day and more preferably about 10 to 100 μg to about 1 mg/day, most preferably about 30 μg to about 500 μg /day, for a 70 kg patient, administered in a single or divided doses. The exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin whenever the suppression of food intake, or weight lowering is desired, for example, at the first sign of symptoms or shortly after diagnosis of obesity, diabetes mellitus, or insulin-resistance syndrome. Administration may be by injection, preferably subcutaneous or intramuscular. Orally active compounds may be taken orally, however dosages should be increased 5-10 fold.

The optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.

To assist in understanding the present invention, the following Examples are included. The experiments relating to this invention should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.

10 EXAMPLE 1: Exendin Injections Reduced the Food Intake of
 Normal Mice

All mice (NIH:Swiss mice) were housed in a stable environment of 22 (± 2)° C, 60 (± 10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with *ad libitum* access to food (Teklad: LM 485; Madison, WI) and water except as noted, for at least two weeks before the experiments.

20 All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μ l/kg) of either saline or exendin-4 at doses of 0.1, 1.0, 10 and 100 μ g/kg and were immediately presented with a pre-weighed food pellet (Teklad LM 485).

25 The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten.

Figure 1 depicts cumulative food intake over periods of 0.5, 1, 2 and 6hr in overnight-fasted normal NIH:Swiss

mice following ip injection of saline, 2 doses of GLP-1, or 4 doses of exendin-4. At doses up to 100µg/kg, GLP-1 had no effect on food intake measured over any period, a result consistent with that previously reported (Bhavsar, S.P., et al., Soc. Neurosci. Abstr. 21:460 (188.8) (1995); and Turton, M.D., Nature, 379:69-72, (1996)).

In contrast, exendin-4 injections potently and dose-dependently inhibited food intake. The ED₅₀ for inhibition of food intake over 30 min was 1µg/kg, which is a level about as potent as amylin (ED₅₀ 3.6µg/kg) or the prototypical peripheral satiety agent, CCK (ED₅₀ 0.97µg/kg) as measured in this preparation. However, in contrast to the effects of amylin or CCK, which abate after 1-2 hours, the inhibition of food intake with exendin-4 was still present after at least 6 hours after injection.

EXAMPLE 2: Exendin Reduced the Food Intake of Obese Mice

All mice (female ob/ob mice) were housed in a stable environment of 22 (±2)° C, 60 (±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with *ad libitum* access to food (Teklad: LM 485) and water except as noted, for at least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 µl/kg) of either saline or exendin-4 at doses

of 0.1, 1.0 and 10 $\mu\text{g/kg}$ (female ob/ob mice) and were immediately presented with a pre-weighed food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1 -hr, 2-hr and 6-hr intervals to determine the amount of food eaten.

Figure 2 depicts the effect of exendin-4 in the ob/ob mouse model of obesity. The obese mice had a similar food intake-related response to exendin as the normal mice. Moreover, the obese mice were not hypersensitive to exendin, as has been observed with amylin and leptin (Young, A.A., et al., Program and Abstracts, 10th International Congress of Endocrinology, June 12-15, 1996 San Francisco, pg 419 (P2-58)).

EXAMPLE 3: Intracerebroventricular Injections of Exendin
Inhibited Food Intake in Rats

All rats (Harlan Sprague-Dawley) were housed in a stable environment of 22 (± 2)° C, 60 (± 10)% humidity and a 12:12 light:dark cycle; with lights on at 0600. Rats were obtained from Zivic Miller with an intracerebroventricular cannula (ICV cannula) implanted (coordinates determined by actual weight of animals and referenced to Paxinos, G. and Watson, C. "The Rat Brain in stereotaxic coordinates," second edition. Academic Press) and were individually housed in standard cages with *ad libitum* access to food (Teklad: LM 485) and water for at least one week before the experiments.

All injections were given between the hours of 1700

and 1800. The rats were habituated to the ICV injection procedure at least once before the ICV administration of compound. All rats received an ICV injection (2 μ l/30 seconds) of either saline or exendin-4 at doses of 0.01, 0.03, 0.1, 0.3, and 1.0 μ g. All animals were then presented with pre-weighed food (Teklad LM 485) at 1800, when the lights were turned off. The amount of food left was weighed at 2-hr, 12-hr and 24-hr intervals to determine the amount of food eaten by each animal.

Figure 3 depicts a dose-dependent inhibition of food intake in rats that received doses greater than 0.1 μ g/rat. The ED₅₀ was \approx 0.1 μ g, exendin-4 is thus \approx 100-fold more potent than intracerebroventricular injections of GLP-1 as reported by Turton, M.D., et al. (Nature 379:69-72 (1996)).

EXAMPLE 4: Exendin Agonists Reduced the Food Intake in Mice

All mice (NIH:Swiss mice) were housed in a stable environment of 22 (\pm 2)° C, 60 (\pm 10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with *ad libitum* access to food (Teklad: LM 485; Madison, WI) and water except as noted, for at least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an

intraperitoneal injection (5 μ l/kg) of either saline or test compound at doses of 1, 10, and 100 μ g/kg and immediately presented with a food pellet (Teklad LM 485).

The food pellet was weighed at 30-minute, 1-hr, 2-hr and 5 6-hr intervals to determine the amount of food eaten.

Figure 4 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-4 (1-30) ("Compound 1") in doses of 1, 10 and 100 10 μ g/kg.

Figure 5 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-4 (1-30) amide ("Compound 2") in doses of 1, 10 15 and 100 μ g/kg.

Figure 6 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-4 (1-28) amide ("Compound 3") in doses of 1, 10 20 and 100 μ g/kg.

Figure 7 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or ¹⁴Leu, ²⁵Phe exendin-4 amide ("Compound 4") in doses of 1, 10 25 and 100 μ g/kg.

Figure 8 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide ("Compound 5") in doses

of 1, 10 and 100 $\mu\text{g/kg}$.

Figure 9 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide ("Compound 6") in doses of 1, 10 and 100 $\mu\text{g/kg}$.

EXAMPLE 5

Preparation of amidated peptide having SEQ. ID. NO. 9

The above-identified peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. However, at some positions coupling was less efficient than expected and double couplings were required. In particular, residues Asp₉, Thr, and Phe₆, all required double coupling. Deprotection (Fmoc group removal) of the growing peptide chain using piperidine was not always efficient. Double deprotection was required at positions Arg₂₀, Val₁₉, and Leu₁₄. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The

precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 55%.

Used in purification steps and analysis were Solvent
5 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column.
10 Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M):
15 calculated 4131.7; found 4129.3.

EXAMPLE 6

Preparation of Peptide having SEQ. ID. NO. 10

20 The above-identified peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a
25 similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 25% to 75% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 21.5

minutes. Electrospray Mass Spectrometry (M): calculated 4168.6; found 4171.2.

EXAMPLE 7

5 Preparation of Peptide having SEQ. ID. NO. 11

The above-identified peptide was assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
10 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
15 Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9
minutes. Electrospray Mass Spectrometry (M): calculated
4147.6; found 4150.2.

20

EXAMPLE 8

Preparation of Peptide having SEQ. ID. NO. 12

The above-identified peptide was assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
25 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis were Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

Analytical RP-HPLC (gradient 35% to 65% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.7 minutes. Electrospray Mass Spectrometry (M): calculated
5 4212.6; found 4213.2.

EXAMPLE 9

Preparation of Peptide having SEQ. ID. NO. 13

10 The above-identified peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
15 similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 16.3
20 minutes. Electrospray Mass Spectrometry (M): calculated
4262.7; found 4262.4.

EXAMPLE 10

Preparation of Peptide having SEQ. ID. NO. 14

25

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.),

cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6

10

EXAMPLE 11Preparation of Peptide having SEQ. ID. NO. 15

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7.

25

EXAMPLE 12Preparation of Peptide having SEQ. ID. NO. 16

5 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
10 similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 4172.6

EXAMPLE 13Preparation of Peptide having SEQ. ID. NO. 17

20 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
25 cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4186.6

5

EXAMPLE 14Preparation of Peptide having SEQ. ID. NO. 18

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
10 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4200.7

20

EXAMPLE 15Preparation of Peptide having SEQ. ID. NO. 19

The above-identified peptide is assembled on 4-(2'-
25 4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A

(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
5 product peptide. Electrospray Mass Spectrometry (M):
calculated 4200.7

EXAMPLE 16

Preparation of Peptide having SEQ. ID. NO. 20

10

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
15 cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
20 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4202.7.

EXAMPLE 17

Preparation of Peptide having SEQ. ID. NO. 21

25

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using

Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

5 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4145.6.

10

EXAMPLE 18

Preparation of Peptide having SEQ. ID. NO. 22

The above-identified peptide is assembled on 4-(2'-
15 4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
20 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 4184.6.

EXAMPLE 19Preparation of Peptide having SEQ. ID. NO. 23

5 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
10 similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 4145.6.

EXAMPLE 20

20 Preparation of Peptide having SEQ. ID. NO. 24

 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
25 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in

Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7.

5

EXAMPLE 21Preparation of Peptide having SEQ. ID. NO. 25

The above-identified peptide is assembled on 4-(2'-
10 4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
15 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
20 calculated 4172.6.

EXAMPLE 22Preparation of Peptide having SEQ. ID. NO. 26

25 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a

similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4115.5.

10

EXAMPLE 23Preparation of Peptide having SEQ. ID. NO. 27

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4188.6.

25

EXAMPLE 24Preparation of Peptide having SEQ. ID. NO. 28

5 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
10 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
15 calculated 4131.6.

EXAMPLE 25Preparation of Peptide having SEQ. ID. NO. 29

20 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
25 similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 4172.6.

EXAMPLE 26

5 Preparation of Peptide having SEQ. ID. NO. 30

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
10 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
15 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4145.6.

20

EXAMPLE 27

Preparation of Peptide having SEQ. ID. NO. 31

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
25 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Additional double couplings are
required at the thioproline positions 38, 37, 36 and 31.

Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4266.8.

EXAMPLE 28

Preparation of Peptide having SEQ. ID. NO. 32

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4246.8.

EXAMPLE 29

Preparation of Peptide having SEQ. ID. NO. 33

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide

norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4250.8.

EXAMPLE 30

Preparation of Peptide having SEQ. ID. NO. 34

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4234.8.

EXAMPLE 31Preparation of Peptide having SEQ. ID. NO. 35

5 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
10 similar way to Example 5. Additional double couplings are
required at the thioproline positions 38, 37, 36 and 31.
Used in analysis are Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient
30% to 60% Solvent B in Solvent A over 30 minutes) of the
15 lyophilized peptide is then carried out to determine the
retention time of the product peptide. Electrospray Mass
Spectrometry (M): calculated 4209.8.

EXAMPLE 32

20 Preparation of Peptide having SEQ. ID. NO. 36

 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
25 Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Additional double couplings are
required at the homoproline positions 38, 37, 36 and 31.
Used in analysis are Solvent A (0.1% TFA in water) and

Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4193.7.

EXAMPLE 33

Preparation of Peptide having SEQ. ID. NO. 37

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3858.2.

EXAMPLE 34

Preparation of Peptide having SEQ. ID. NO. 38

The above-identified peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using

Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 5. Additional double couplings are
required at the N-methylalanine positions 38, 37 and 36.
5 Used in analysis are Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient
30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the
retention time of the product peptide. Electrospray Mass
10 Spectrometry (M): calculated 3940.3.

EXAMPLE 35

Preparation of Peptide having SEQ. ID. NO. 39

15 The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
20 cleaved from the resin, deprotected and purified in a
similar way to Example 5. Additional double couplings are
required at the N-methylalanine positions 38, 37, 36 and
31. Used in analysis are Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient
25 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the
retention time of the product peptide. Electrospray Mass
Spectrometry (M): calculated 3801.1.

EXAMPLE 36

Preparation of C-terminal carboxylic acid Peptides
corresponding to the above C-terminal amide sequences.

5

The above peptides of Examples 5 to 35 are assembled on the so called Wang resin (p-alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

10
15EXAMPLE 37

20

Preparation of Peptide having SEQ ID NO. 7

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly-NH₂ [SEQ. ID. NO. 7]

25

The above amidated peptide was assembled on 4-(2',4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the

30

synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved
5 using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL)
10 and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%.

Used in purification steps and analysis were Solvent
15 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column.
20 Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 18.9 minutes. Electrospray Mass Spectrometry (M):
25 calculated 3408.0; found 3408.9.

EXAMPLE 38Preparation of Peptide having SEQ ID NO. 40

5 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 40]

The above amidated peptide was assembled on 4-(2'-4'-
10 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent A
15 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 40% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9
minutes. Electrospray Mass Spectrometry (M): calculated
20 3294.7; found 3294.8.

EXAMPLE 39Preparation of Peptide having SEQ ID NO. 41

25

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 41]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 29% to 36% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 20.7 minutes. Electrospray Mass Spectrometry (M): calculated 3237.6; found 3240.

15

EXAMPLE 40Preparation of Peptide having SEQ ID NO. 42

His Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 42]

20

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

25

Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated
5 3251.6; found 3251.5.

EXAMPLE 41

Preparation of Peptide having SEQ ID NO. 43

10 His Gly Glu Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 43]

The above amidated peptide was assembled on 4-(2'-4'-
15 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent A
20 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 36% to 46% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 13.1
minutes. Electrospray Mass Spectrometry (M): calculated
25 3207.6; found 3208.3.

EXAMPLE 42Preparation of Peptide having SEQ ID NO. 44

His Gly Glu Gly Thr Ala Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 44]

The above amidated peptide was assembled on 4-(2'-4'-
dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
10 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis were Solvent
A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 35% to 45% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 12.8
minutes. Electrospray Mass Spectrometry (M): calculated
3161.5; found 3163.

20

EXAMPLE 43Preparation of Peptide having SEQ ID NO. 45

His Gly Glu Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Leu
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 45]

The above-identified amidated peptide was assembled

on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
5 purified in a similar way to Example 37. Used in analysis
were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of
10 15.2 minutes. Electrospray Mass Spectrometry (M):
calculated 3221.6; found 3222.7.

EXAMPLE 44

Preparation of Peptide having SEQ ID NO. 46

15

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 46]

20

The above-identified amidated peptide was assembled
on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
25 purified in a similar way to Example 37. Used in analysis
were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide

gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3199.4.

5

EXAMPLE 45Preparation of Peptide having SEQ ID NO. 47

10

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 47]

15

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.7 minutes. Electrospray Mass Spectrometry (M): calculated 3221.6; found 3221.6.

20

25

EXAMPLE 46Preparation of Peptide having SEQ ID NO. 48

30

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 48]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 18.1 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3180.9.

15 EXAMPLE 47

Preparation of Peptide having SEQ ID NO. 49

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Leu
20 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 49]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

gave product peptide having an observed retention time of 17.0 minutes. Electrospray Mass Spectrometry (M): calculated 3180.6; found 3182.8.

5

EXAMPLE 48Preparation of Peptide having SEQ ID NO. 50

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 50]

10

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3195.9.

15

20

25

EXAMPLE 49Preparation of Peptide having SEQ ID NO. 51

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu

Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 51]

The above-identified amidated peptide was assembled
5 on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
10 purified in a similar way to Example 37. Used in analysis
were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of
17.9 minutes. Electrospray Mass Spectrometry (M):
15 calculated 3179.6; found 3179.0.

EXAMPLE 50

Preparation of Peptide having SEQ ID NO. 52

20

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 52]

25

The above-identified amidated peptide was assembled
on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and

purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.0.

EXAMPLE 51

Preparation of Peptide having SEQ ID NO. 53

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 53]

The above-identified peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 13.7 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3179.0.

EXAMPLE 52Preparation of Peptide having SEQ ID NO. 54

5 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 54]

The above-identified amidated peptide was assembled
10 on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
15 were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of
14.0 minutes. Electrospray Mass Spectrometry (M):
20 calculated 3209.6; found 3212.8.

EXAMPLE 53Preparation of Peptide having SEQ ID NO. 55

25 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 55]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3152.5; found 3153.5.

EXAMPLE 54

Preparation of Peptide having SEQ ID NO. 56

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 56]

20

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

gave product peptide having an observed retention time of 12.1 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3197.7.

5

EXAMPLE 55Preparation of Peptide having SEQ ID NO. 57

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Ala Phe Leu Lys Asn-NH₂
10 [SEQ. ID. NO. 57]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B
20 in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 10.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.5.

25

EXAMPLE 56Preparation of Peptide having SEQ ID NO. 58

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂

[SEQ. ID. NO. 58]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.5 minutes. Electrospray Mass Spectrometry (M): calculated 3161.5; found 3163.0.

15

EXAMPLE 57

Preparation of Peptide having SEQ ID NO. 59

20 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn-NH₂
[SEQ. ID. NO. 59]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B

30

in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.5 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3199.

5

EXAMPLE 58Preparation of Peptide having SEQ ID NO. 60

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
10 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Ala Asn-NH₂
[SEQ. ID. NO. 60]

The above-identified amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis
20 were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3183.7.

25

EXAMPLE 59Preparation of Peptide having SEQ ID NO. 61

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala-NH₂
[SEQ. ID. NO. 61]

The above-identified amidated peptide was assembled
on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
15 were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of
22.8 minutes. Electrospray Mass Spectrometry (M):
calculated 3194.6; found 3197.6.

20

EXAMPLE 60Preparation of Peptide having SEQ ID NO. 62

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO.
62]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4099.6.

EXAMPLE 61

Preparation of Peptide having SEQ ID NO. 63

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO.
63]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA

in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 4042.5.

EXAMPLE 62

Preparation of Peptide having SEQ ID NO. 64

10 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 64]

The above-identified peptide is assembled on 4-(2'-
15 4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis are Solvent A
20 (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 4002.4

EXAMPLE 63Preparation of Peptide having SEQ ID NO. 65

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 65]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
15 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3945.4.

20

EXAMPLE 64Preparation of Peptide having SEQ ID NO. 66

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
25 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 66]

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
5 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3905.3.

EXAMPLE 65

Preparation of Peptide having SEQ ID NO. 67

15

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 67]

20

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
25 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3848.2.

5

EXAMPLE 66Preparation of Peptide having SEQ ID NO. 68

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
10 Gly Gly Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 68]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
20 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3808.2.

25

EXAMPLE 67Preparation of Peptide having SEQ ID NO. 69

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 69]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3751.1.

20

EXAMPLE 68Preparation of Peptide having SEQ ID NO. 70

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly-NH₂ [SEQ. ID. NO. 70]

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
5 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3737.1.

EXAMPLE 69

Preparation of Peptide having SEQ ID NO. 71

15

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly-NH₂ [SEQ. ID. NO. 71]

20

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
25 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1.

5

EXAMPLE 70Preparation of Peptide having SEQ ID NO. 72

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
10 Gly Gly Pro Ser Ser-NH₂ [SEQ. ID. NO. 72]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
20 in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1

25

EXAMPLE 71Preparation of Peptide having SEQ ID NO. 73

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
30 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser-NH₂ [SEQ. ID. NO. 73]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3623.0.

15

EXAMPLE 72Preparation of Peptide having SEQ ID NO. 74

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
20 Gly Gly Pro Ser-NH₂ [SEQ. ID. NO. 74]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA

in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3593.0

EXAMPLE 73

Preparation of Peptide having SEQ ID NO. 75

10 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser-NH₂ [SEQ. ID. NO. 75]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
20 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3535.9

EXAMPLE 74Preparation of Peptide having SEQ ID NO. 76

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro-NH₂ [SEQ. ID. NO. 76]

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
10 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
15 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3505.9.

20

EXAMPLE 75Preparation of Peptide having SEQ ID NO. 77

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro-NH₂ [SEQ. ID. NO. 77]

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
5 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3448.8.

EXAMPLE 76

Preparation of Peptide having SEQ ID NO. 78

15

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly-NH₂ [SEQ. ID. NO. 78]

20

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
25 similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3351.7.

5

EXAMPLE 77Preparation of Peptide having SEQ ID NO. 79

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
10 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly-NH₂ [SEQ. ID. NO. 79]

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
15 norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 37. Used in analysis are Solvent A
(0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
20 Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3351.8.

25

EXAMPLE 78Preparation of Peptide having SEQ ID NO. 80

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly-NH₂ [SEQ. ID. NO. 80]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
15 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3294.7.

20

EXAMPLE 79Preparation of Peptide having SEQ ID NO. 81

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly tPro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID.
NO. 81]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 37,36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4197.1.

15

EXAMPLE 80Preparation of Peptide having SEQ ID NO. 82

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
20 Gly Gly Pro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID.
NO. 82]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings

are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4179.1.

EXAMPLE 81

10 Preparation of Peptide having SEQ ID NO. 83

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly NMeala Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO.
15 83]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

calculated 3948.3.

EXAMPLE 82

Preparation of Peptide having SEQ ID NO. 84

5

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly NMeala Ser Ser Gly Ala NMeala Nmeala-NH₂ [SEQ. ID.
NO. 84]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
15 Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Double couplings
are required at residues 36 and 31. Used in analysis are
Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in
ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
20 Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3840.1.

EXAMPLE 83Preparation of Peptide having SEQ ID NO. 85

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH₂ [SEQ. ID. NO.
85]

The above-identified amidated peptide is assembled on
10 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 37. Double couplings
are required at residues 36 and 31. Used in analysis are
Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in
ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
20 then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4050.1.

EXAMPLE 84Preparation of Peptide having SEQ ID NO. 86

25

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly hPro Ser Ser Gly Ala hPro-NH₂ [SEQ. ID. NO. 86]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. A double coupling is required at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3937.1

15

EXAMPLE 85Preparation of Peptide having SEQ ID NO. 87

Arg Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
 Gly Gly Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 87]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis

are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3827.2.

EXAMPLE 86

Preparation of Peptide having SEQ ID NO. 88

10

His Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly-NH₂ [SEQ. ID. NO. 88]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3394.8.

20

25

EXAMPLE 87Preparation of Peptide having SEQ ID NO. 89

His Gly Glu Gly Thr Naphthylala Thr Ser Asp Leu Ser Lys
5 Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu
Lys Asn-NH₂ [SEQ. ID. NO. 89]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3289.5.

20

EXAMPLE 88Preparation of Peptide having SEQ ID NO. 90

His Gly Glu Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂,
[SEQ. ID. NO. 90]

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
5 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3280.7.

EXAMPLE 89

Preparation of Peptide having SEQ ID NO. 91

15 His Gly Glu Gly Thr Phe Ser Thr Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 91]

20 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
25 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3294.7.

5

EXAMPLE 90Preparation of Peptide having SEQ ID NO. 92

His Gly Glu Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met
Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
10 [SEQ. ID. NO. 92]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
15 is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3250.7.
20

EXAMPLE 91

25

Preparation of Peptide having SEQ ID NO. 93

His Gly Glu Gly Thr Phe Thr Ser Asp pentylgly Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys

Asn-NH₂ [SEQ. ID. NO. 93]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
10 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3253.5.

15

EXAMPLE 92

Preparation of Peptide having SEQ ID NO. 94

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
20 Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Phe Leu
Lys Asn-NH₂ [SEQ. ID. NO. 94]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
25 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis

are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3289.5.

EXAMPLE 93

Preparation of Peptide having SEQ ID NO. 95

10

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu Trp Leu Lys
Asn-NH₂ [SEQ. ID. NO. 95]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3183.4.

20

25

EXAMPLE 94Preparation of Peptide having SEQ ID NO. 96

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 96]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Used in analysis
15 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3237.6.

20

EXAMPLE 95Preparation of Peptide having SEQ ID NO. 97

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser-NH₂ [SEQ. ID. NO. 97]

The above-identified amidated peptide is assembled on

4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
5 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
10 product peptide. Electrospray Mass Spectrometry (M):
calculated 3637.9.

EXAMPLE 96

Preparation of Peptide having SEQ ID NO. 98

15 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly-NH₂ [SEQ. ID. NO. 98]

20 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
25 purified in a similar way to Example 37. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3309.7.

5

EXAMPLE 97Preparation of Peptide having SEQ ID NO. 99

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
10 Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH₂ [SEQ. ID. NO.
99]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 37. Double couplings
are required at residues 36 and 31. Used in analysis are
20 Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in
ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is
then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3711.1.

EXAMPLE 98

Preparation of C-terminal carboxylic acid peptides
corresponding to the above C-terminal amide sequences for
SEQ ID NOS. 7, 40-61, 68-75, 78-80 and 87-96

5

Peptides having the sequences of SEQ ID NOS. 7, 40-61, 68-75, 78-80 and 87-96 are assembled on the so called Wang resin (p-alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

10
15

20

EXAMPLE 99

Preparation of C-terminal carboxylic acid peptides
corresponding to the above C-terminal amide sequences for
SEQ ID NOS. 62-67, 76, 77 and 81-86

25

Peptides having the sequences of SEQ ID NOS. 62-67, 76, 77 and 81-86 are assembled on the 2-chlorotriethylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino

acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

10

EXAMPLE 100Preparation of Peptide having SEQ ID NO. 100

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 100]

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems,

Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%.

Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.2 minutes. Electrospray Mass Spectrometry (M): calculated 3171.6; found 3172.

EXAMPLE 101

Preparation of Peptide having SEQ ID NO. 101

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 101]

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.),

cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.

10

EXAMPLE 102Preparation of Peptide having SEQ ID NO. 102

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 102]

The above amidated peptide was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.2 minutes. Electrospray Mass Spectrometry (M): calculated 3251.6; found 3253.3.

EXAMPLE 103Preparation of Peptide having SEQ ID NO. 103

5 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 103]

The above amidated peptide was assembled on 4-(2'-4'-
10 dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.),
cleaved from the resin, deprotected and purified in a
similar way to Example 100. Used in analysis were Solvent
15 A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 35% to 45% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 16.3
minutes. Electrospray Mass Spectrometry (M): calculated
20 3193.6; found 3197.

EXAMPLE 104Preparation of Peptide having SEQ ID NO. 104

25 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 104]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3228.6.

EXAMPLE 105

Preparation of Peptide having SEQ ID NO. 105

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 105]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3234.7.

5

EXAMPLE 106Preparation of Peptide having SEQ ID NO. 106

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
10 [SEQ. ID. NO. 106]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
20 in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3308.7.

25

EXAMPLE 107Preparation of Peptide having SEQ ID NO. 107

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

[SEQ. ID. NO. 107]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
10 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3250.7

15

EXAMPLE 108

Preparation of Peptide having SEQ ID NO. 108

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
20 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 108]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
25 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA

in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3252.6.

EXAMPLE 109

Preparation of Peptide having SEQ ID NO. 109

10 Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 109]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
20 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3200.6.

EXAMPLE 110Preparation of Peptide having SEQ ID NO. 110

Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
5 [SEQ. ID. NO. 110]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
10 mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
15 in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3143.5.

20

EXAMPLE 111Preparation of Peptide having SEQ ID NO. 111

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 111]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3214.6.

EXAMPLE 112

Preparation of Peptide having SEQ ID NO. 112

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂ [SEQ. ID. NO. 112]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

calculated 3157.5.

EXAMPLE 113

Preparation of Peptide having SEQ ID NO. 113

5

Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 113]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3184.6.

EXAMPLE 114

Preparation of Peptide having SEQ ID NO. 114

25

Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 114]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3127.5.

15

EXAMPLE 115Preparation of Peptide having SEQ ID NO. 115

Ala Gly Asp Gly Thr NaphthylAla Thr Ser Asp Leu Ser Lys
Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
20 Lys Asn-NH₂ [SEQ. ID. NO. 115]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B

in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3266.4.

5

EXAMPLE 116Preparation of Peptide having SEQ ID NO. 116

Ala Gly Asp Gly Thr Naphthylala Thr Ser Asp Leu Ser Lys
10 Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu
Lys Asn-NH₂ [SEQ. ID. NO. 116]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
20 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3209.4.

25

EXAMPLE 117Preparation of Peptide having SEQ ID NO. 117

Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 117]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
10 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 3200.6.

EXAMPLE 118

Preparation of Peptide having SEQ ID NO. 118

20

Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 118].

25

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and

purified in a similar way³ to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
5 is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3143.5.

EXAMPLE 119

10 Preparation of Peptide having SEQ ID NO. 119

Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 119]

15 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
20 Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
25 is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3198.6.

EXAMPLE 120Preparation of Peptide having SEQ ID NO. 120

Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 120]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3141.5.

20

EXAMPLE 121Preparation of Peptide having SEQ ID NO. 121

Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 121]

The above-identified peptide is assembled on 4-(2'-
4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide

norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3170.6.

EXAMPLE 122

Preparation of Peptide having SEQ ID NO. 122

Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 122]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

calculated 3113.5.

EXAMPLE 123

Preparation of Peptide having SEQ ID NO. 123

5

Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 123]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3228.6.

EXAMPLE 124

Preparation of Peptide having SEQ ID NO. 124

25

Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 124]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3171.6.

15

EXAMPLE 125Preparation of Peptide having SEQ ID NO. 125

Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 125]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B

25

in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.

5

EXAMPLE 126Preparation of Peptide having SEQ ID NO. 126

Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu
10 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 126]

The above-identified amidated peptiden is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
20 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.4.

25

EXAMPLE 127Preparation of Peptide having SEQ ID NO. 127

Ala Gly Asp Gly Thr Phe Thr Ser Asp Pentylgly Ser Lys Gln
5 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn-NH₂ [SEQ. ID. NO. 127]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3230.4.

20

EXAMPLE 128Preparation of Peptide having SEQ ID NO. 128

Ala Gly Asp Gly Thr Phe Thr Ser Asp Pentylgly Ser Lys Gln
25 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 128]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3198.6.

EXAMPLE 129

Preparation of Peptide having SEQ ID NO. 129

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 129]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

calculated 3141.5.

EXAMPLE 130

Preparation of Peptide having SEQ ID NO. 130

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 130]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3157.5.

EXAMPLE 131

Preparation of Peptide having SEQ ID NO. 131

25

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 131]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.4.

15

EXAMPLE 132Preparation of Peptide having SEQ ID NO. 132

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 132]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B

25

in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.6.

5

EXAMPLE 133Preparation of Peptide having SEO ID NO. 133

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Met
10 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 133]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
20 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3100.5.

25

EXAMPLE 134Preparation of Peptide having SEO ID NO. 134

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 134]

5 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
10 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
15 product peptide. Electrospray Mass Spectrometry (M):
calculated 3100.5.

EXAMPLE 135

Preparation of Peptide having SEQ ID NO. 135

20

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 135]

25 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and

purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
5 is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3154.5.

EXAMPLE 136

10 Preparation of Peptide having SEQ ID NO. 136

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 136]

15 The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
20 Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
25 is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3115.5.

EXAMPLE 137Preparation of Peptide having SEQ ID NO. 137

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
5 Pentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
Lys Asn-NH₂ [SEQ. ID. NO. 137]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3212.4.

20

EXAMPLE 138Preparation of Peptide having SEQ ID NO. 138

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
25 Pentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu
Lys Asn-NH₂ [SEQ. ID. NO. 138]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3173.4.

EXAMPLE 139

Preparation of Peptide having SEQ ID NO. 139

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 139]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.

EXAMPLE 140Preparation of Peptide having SEQ ID NO. 140

5 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 140]

The above-identified amidated peptide is assembled on
10 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
15 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
20 calculated 3099.5.

EXAMPLE 141Preparation of Peptide having SEQ ID NO. 141

25 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 141]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.

EXAMPLE 142

Preparation of Peptide having SEQ ID NO. 142

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 142]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 3099.5.

EXAMPLE 143

5 Preparation of Peptide having SEQ ID NO. 143

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 143]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
15 Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
20 is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3156.6.

EXAMPLE 144

25 Preparation of Peptide having SEQ ID NO. 144

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 144]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.

15

EXAMPLE 145Preparation of Peptide having SEQ ID NO. 145

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 145]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

25

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3186.6.

5

EXAMPLE 146Preparation of Peptide having SEQ ID NO. 146

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
10 [SEQ. ID. NO. 146]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
20 in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3129.5.

25

EXAMPLE 147Preparation of Peptide having SEQ ID NO. 147

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 147]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3129.5.

15

EXAMPLE 148Preparation of Peptide having SEQ ID NO. 148

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 148]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B

in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3072.4.

5

EXAMPLE 149Preparation of Peptide having SEQ ID NO. 149

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
10 Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 149]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
20 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3172.5.

25

EXAMPLE 150Preparation of Peptide having SEQ ID NO. 150

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
5 Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 150]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3115.5.

20

EXAMPLE 151Preparation of Peptide having SEQ ID NO. 151

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Trp Leu
Lys Asn-NH₂ [SEQ. ID. NO. 151]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis
5 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
10 calculated 3266.4.

EXAMPLE 152

Preparation of Peptide having SEQ ID NO. 152

15 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Phe Leu
Lys Asn-NH₂ [SEQ. ID. NO. 152]

The above-identified amidated peptide is assembled on
20 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis
25 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

calculated 3209.4.

EXAMPLE 153

Preparation of Peptide having SEQ ID NO. 153

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Val Glu Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 153]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3200.6.

EXAMPLE 154

Preparation of Peptide having SEQ ID NO. 154

25

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Val Glu Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 154]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.

15

EXAMPLE 155Preparation of Peptide having SEQ ID NO. 155

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu Trp Leu Lys
Asn-NH₂, [SEQ. ID. NO. 155]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B

25

in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3216.5.

5

EXAMPLE 156Preparation of Peptide having SEQ ID NO. 156

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
10 Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu Phe Leu Lys
Asn-NH₂ [SEQ. ID. NO. 156]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
20 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3159.4.

25

EXAMPLE 157Preparation of Peptide having SEQ ID NO. 157

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Trp Leu Lys Asn-NH₂
[SEQ. ID. NO. 157]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray-Mass Spectrometry (M):
calculated 3200.6.

20

EXAMPLE 158Preparation of Peptide having SEQ ID NO. 158

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn-NH₂
[SEQ. ID. NO. 158]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis
5 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
10 calculated 3143.5.

EXAMPLE 159

Preparation of Peptide having SEQ ID NO. 159

15 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂
[SEQ. ID. NO. 159]

The above-identified amidated peptide is assembled on
20 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis
25 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

calculated 3099.5.

EXAMPLE 160

Preparation of Peptide having SEQ ID NO. 160

5

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂
[SEQ. ID. NO. 160]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3081.4.

EXAMPLE 161

Preparation of Peptide having SEQ ID NO. 161

25

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Ala Lys Asn-NH₂
[SEQ. ID. NO. 161]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.

15

EXAMPLE 162Preparation of Peptide having SEQ ID NO. 162

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn-NH₂
[SEQ. ID. NO. 162]

20

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

25

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.

5

EXAMPLE 163Preparation of Peptide having SEQ ID NO. 163

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Ala Asn-NH₂
10 [SEQ. ID. NO. 163]

15

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.

20

25

EXAMPLE 164Preparation of Peptide having SEQ ID NO. 164

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Ala Asn-NH₂

[SEQ. ID. NO. 164]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
10 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3100.4.

15

EXAMPLE 165

Preparation of Peptide having SEQ ID NO. 165

Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
20 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Ala-NH₂
[SEQ. ID. NO. 165]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
25 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA

in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):

5 calculated 3171.6.

EXAMPLE 166

Preparation of Peptide having SEQ ID NO. 166

10 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala-NH₂
[SEQ. ID. NO. 166]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
20 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3114.5.

EXAMPLE 167Preparation of Peptide having SEQ ID NO. 167

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO.
167]

The above-identified amidated peptide is assembled on
10 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
15 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
20 calculated 4033.5.

EXAMPLE 168Preparation of Peptide having SEQ ID NO. 168

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH₂ [SEQ. ID. NO.
168]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3984.4.

EXAMPLE 169

Preparation of Peptide having SEQ ID NO. 169

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH₂ [SEQ. ID. NO. 169]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide

is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4016.5.

5

EXAMPLE 170Preparation of Peptide having SEQ ID NO. 170

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
10 Gly Gly Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 170]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
20 in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3861.3.

25

EXAMPLE 171Preparation of Peptide having SEQ ID NO. 171

Ala Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn

Gly Gly Pro Ser Ser Gly Ala Pro-NH₂ [SEQ. ID. NO. 171]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
5 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
10 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3746.1.

15

EXAMPLE 172

Preparation of Peptide having SEQ ID NO. 172

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
20 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 172]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
25 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA

in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
5 calculated 3742.1.

EXAMPLE 173

Preparation of Peptide having SEQ ID NO. 173

10 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 173]

The above-identified amidated peptide is assembled on
15 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
20 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
25 calculated 3693.1.

EXAMPLE 174Preparation of Peptide having SEQ ID NO. 174

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly-NH₂ [SEQ. ID. NO. 174]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3751.2.

20

EXAMPLE 175Preparation of Peptide having SEQ ID NO. 175

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser-NH₂ [SEQ. ID. NO. 175]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis
5 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M):
10 calculated 3634.1.

EXAMPLE 176

Preparation of Peptide having SEQ ID NO. 176

15 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser-NH₂, [SEQ. ID. NO. 176]

The above-identified amidated peptide is assembled on
20 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis
25 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. (Electrospray Mass Spectrometry (M):

calculated 3526.9.

EXAMPLE 177

Preparation of Peptide having SEQ ID NO. 177

5

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser-NH₂ [SEQ. ID. NO. 177]

10

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
15 purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
20 product peptide. Electrospray Mass Spectrometry (M):
calculated 3477.9.

EXAMPLE 178

Preparation of Peptide having SEQ ID NO. 178

25

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro-NH₂ [SEQ. ID. NO. 178]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3519.9.

15

EXAMPLE 179Preparation of Peptide having SEQ ID NO. 179

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
20 Gly Gly-NH₂, [SEQ. ID. NO. 179]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B

in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3307.7.

5

EXAMPLE 180Preparation of Peptide having SEQ ID NO. 180

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
10 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly-NH₂ [SEQ. ID. NO. 180]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
15 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
20 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3186.5.

25

EXAMPLE 181Preparation of Peptide having SEQ ID NO. 181

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
 Gly Gly tPro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID.
 NO. 181]

5

The above-identified amidated peptide is assembled on
 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
 acetamide norleucine MBHA resin (Novabiochem, 0.55
 mmole/g) using Fmoc-protected amino acids (Applied
 Biosystems, Inc.), cleaved from the resin, deprotected and
 purified in a similar way to Example 100. Double couplings
 are required at residues 37,36 and 31. Used in analysis
 are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
 in ACN): Analytical RP-HPLC (gradient 30% to 60% Solvent B
 in Solvent A over 30 minutes) of the lyophilized peptide
 is then carried out to determine the retention time of the
 product peptide. Electrospray Mass Spectrometry (M):
 calculated 4121.1.

20

EXAMPLE 182

Preparation of Peptide having SEQ ID NO. 182

His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
 Gly Gly Pro Ser Ser Gly Ala tPro tPro tPro-NH₂ [SEQ. ID.
 NO. 182].

25

The above-identified amidated peptide is assembled on
 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
 acetamide norleucine MBHA resin (Novabiochem, 0.55

mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4173.2.

EXAMPLE 183

Preparation of Peptide having SEQ ID NO. 183

His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly NMeala Ser Ser Gly Ala NMeala NMeala-NH₂ [SEQ. ID.
NO. 183]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is

then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3796.1.

5

EXAMPLE 184Preparation of Peptide having SEQ ID NO. 184

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
10 Gly Gly hPro Ser Ser Gly Ala hPro-NH₂ [SEQ. ID. NO. 184]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. A double coupling is required at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in
20 ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3871.1.

25

EXAMPLE 185Preparation of Peptide having SEQ ID NO. 185

His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
5 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala-NH₂ [SEQ. ID. NO. 185]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
10 acetamide norleucine MBHA resin (Novabiochem, 0.55
mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
15 in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 3750.2.

20

EXAMPLE 186Preparation of Peptide having SEQ ID NO. 186

His Gly Asp Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
25 Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly-NH₂ [SEQ. ID. NO. 186]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy

acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3408.8.

EXAMPLE 187

Preparation of Peptide having SEQ ID NO. 187

Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH₂ [SEQ. ID.
NO. 187]

The above-identified amidated peptide is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the

product peptide. Electrospray Mass Spectrometry (M):
calculated 4120.6.

EXAMPLE 188

5 Preparation of Peptide having SEQ ID NO. 188

Ala Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH₂ [SEQ. ID.
10 NO. 188]

The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy
acetamide norleucine MBHA resin (Novabiochem, 0.55
15 mmole/g) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B
20 in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the
product peptide. Electrospray Mass Spectrometry (M):
calculated 4005.5.

25 EXAMPLE 189

Preparation of C-terminal carboxylic acid peptides
corresponding to the above C-terminal amide sequences for
Peptides having SEQ ID NOS. 100-166, 172-177, 179-180 and
185-188.

C-terminal carboxylic acid peptides corresponding to amidated having SEQ ID NOS. 100-166, 172-177, 179-180 and 185-188 are assembled on the so called Wang resin (p-alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

15

EXAMPLE 190

Preparation of C-terminal carboxylic acid peptides corresponding to the above C-terminal amide sequences for
Peptides having SEQ ID NOS. 167-171, 178 and 181-184.

20

C-terminal carboxylic acid peptides corresponding to amidated SEQ ID NOS. 167-171, 178 and 181-184 are assembled on the 2-chlorotriethylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in

25

ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides
5 an experimentally determined (M).

Various modifications of the invention in addition to those shown and described herein will become apparent to
10 those skilled in the art from the foregoing description and fall within the scope of the following claims.

WE CLAIM:

1. A method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
2. The method according to claim 1 wherein said exendin or exendin agonist is administered parenterally.
3. The method according to claim 2 wherein said parenteral administration is by injection.
4. The method according to claim 3 wherein the injection is a peripheral injection.
5. The method according to claim 1 wherein about 10 μ g-30 μ g to about 5mg of the exendin or exendin agonist is administered per day.
6. The method according to claim 1 wherein about 10 μ g-30 μ g to about 2 mg of the exendin or exendin agonist is administered per day.
7. The method according to claim 1, wherein about 30 μ g to about 500 μ g of the exendin or exendin agonist is administered per day.
8. The method of claim 1 wherein said condition or disorder is obesity.
9. The method of claim 1 wherein said condition or disorder is Type II diabetes.
10. The method of claim 1 wherein said subject is human.
11. The method of claim 1 wherein said condition or disorder is an eating disorder.

12. The method of claim 1 wherein said condition or disorder is insulin-resistance syndrome.

13. A method for reducing the appetite of a subject comprising administering to said subject an appetite-lowering amount of an exendin or an exendin agonist.

14. A method for reducing the weight of a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

15. A method for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

16. The method according to any of claims 1-15 wherein said exendin is exendin-3.

17. The method according to any of claims 1-15 wherein said exendin is exendin-4.

18. The method according to any of claims 1-15 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu,²⁵Phe exendin-4 amide, ¹⁴Leu,²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu,²²Ala,²⁵Phe exendin-4 (1-28) amide.

19. The method according to any of claims 1-15, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting essential of an amylin agonist, a leptin, and a CCK.

20. The method according to any of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula I.

21. The method according to any of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula II.

22. The method according to any of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula III.

23. A pharmaceutical composition for use in the treatment of conditions or disorders associated with hypernutrition comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.

24. The pharmaceutical composition according to claim 21, wherein said exendin is exendin-3.

25. The pharmaceutical composition according to claim 21 wherein said exendin is exendin-4.

26. The pharmaceutical composition according to claim 21 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu,²⁵Phe exendin-4 amide, ¹⁴Leu,²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu,²²Ala,²⁵Phe exendin-4 (1-28) amide.

27. The pharmaceutical composition of claim 21 wherein said therapeutically effective amount is a therapeutically effective amount for a human subject.

28. A pharmaceutical composition for use in reducing the appetite of a subject comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.


29. A pharmaceutical composition for use in reducing the weight of a subject comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.

5 30. A pharmaceutical composition for use in lowering the plasma lipid level of a subject comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier.

10 31. The pharmaceutical composition according to any of claims 21-28, further comprising a therapeutically effective amount of one or more compounds selected from the group consisting essentially of an amylin agonist, a leptin, and a CCK.


1/11

FIG. 1.






2/11

FIG. 2.




3/11

FIG. 3.




4/11

FIG. 4.




5/11

FIG. 5.




6/11

FIG. 6.




7/11

FIG. 7.




8/11



9/11

FIG. 9.



1 Xaa, Xaa, Xaa, Gly Thr Xaa, Xaa, Xaa, Xaa, Ser Lys Gln Xaa, Glu Glu Glu Ala Val Arg Leu
 5
 10
 15
 20
 25
 30
 35
 Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Leu Lys Asn Gly Gly Xaa₁₄ Ser Ser Gly Ala Xaa₁₅ Xaa₁₆ Xaa₁₇ Xaa₁₈-Z

[SEQ. ID. NO.]	Xaa ₁	Xaa ₂	Xaa ₃	Xaa ₄	Xaa ₅	Xaa ₆	Xaa ₇	Xaa ₈	Xaa ₉	Xaa ₁₀	Xaa ₁₁	Xaa ₁₂	Xaa ₁₃	Xaa ₁₄	Xaa ₁₅	Xaa ₁₆	Xaa ₁₇	Xaa ₁₈	Z
9	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
10	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
11	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
12	Tyr	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
13	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Tyr	NH ₂
14	His	Gly	Asp	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
15	His	Gly	Glu	naph	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
16	His	Gly	Glu	Phe	Ser	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
17	His	Gly	Glu	Phe	Ser	Thr	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
18	His	Gly	Glu	Phe	Thr	Thr	Asp	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
19	His	Gly	Glu	Phe	Thr	Ser	Glu	Leu	Leu	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
20	His	Gly	Glu	Phe	Thr	Ser	Asp	pGly	pGly	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
21	His	Gly	Glu	Phe	Thr	Ser	Asp	pGly	pGly	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
22	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	pGly	Phe	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂

FIGURE 10
(Sheet 1 of 2)

11/11

[SEQ. ID. NO.]	Xaa ₁	Xaa ₂	Xaa ₃	Xaa ₄	Xaa ₅	Xaa ₆	Xaa ₇	Xaa ₈	Xaa ₉	Xaa ₁₀	Xaa ₁₁	Xaa ₁₂	Xaa ₁₃	Xaa ₁₄	Xaa ₁₅	Xaa ₁₆	Xaa ₁₇	Xaa ₁₈	Z
23	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	poly	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
24	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	naph	Ile	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
25	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Val	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
26	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Val	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH
27	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	tBuG	Glu	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
28	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	tBuG	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
29	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Asp	Trp	Pro	Pro	Pro	Pro	Ser	NH ₂
30	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Pro	Ser	NH ₂
31	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	tPro	tPro	tPro	tPro	Ser	NH ₂
32	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	tPro	tPro	tPro	Ser	NH ₂
33	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	hPro	hPro	hPro	hPro	Ser	NH ₂
34	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	hPro	hPro	hPro	Ser	NH ₂
35	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Phe	tPro	tPro	tPro	tPro	Ser	NH ₂
36	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	hPro	hPro	hPro	hPro	Ser	NH
37	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	MeAla	MeAla	MeAla	MeAla	Ser	NH
38	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	MeAla	MeAla	MeAla	Ser	NH
39	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	MeAla	MeAla	MeAla	MeAla	Ser	NH

FIGURE 10
(Sheet 2 of 2)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00449

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/16

US CL : 514/2, 866

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 866

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,424,286 A (ENG) 13 June 1995 see entire document.	1-31

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 MAY 1998

Date of mailing of the international search report

29 MAY 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Zohreh Fay

Telephone No. (703) 308-1235

Effect of Exendin-4 and GLP-1 on Food Intake
In NIH/SW Mice
Mean \pm S.E.





FIGURE 1

Effect of Exendin-4 on Food Intake in
Female ob/ob Mice
Mean \pm S.E.



All injections given IP (5 ml/kg) at T=0 minutes

FIGURE 2






FIGURE 3




FIGURE 4




FIGURE 5

**Effect of Compound 3 on Food Intake
In NIH/SW Mice
Mean \pm S.E.**




FIGURE 6




FIGURE 7




FIGURE 8

Effect of Compound 6 on Food Intake
in NIH/SW Mice
Mean \pm S.E.




FIGURE 9

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006
 1007
 1008
 1009
 1010
 1011
 1012
 1013
 1014
 1015
 1016
 1017
 1018
 1019
 1020
 1021
 1022
 1023
 1024
 1025
 1026
 1027
 1028
 1029
 1030
 1031
 1032
 1033
 1034
 1035
 1036
 1037
 1038
 1039
 1040
 1041
 1042
 1043
 1044
 1045
 1046
 1047
 1048
 1049
 1050
 1051
 1052
 1053
 1054
 1055
 1056
 1057
 1058
 1059
 1060
 1061
 1062
 1063
 1064
 1065
 1066
 1067
 1068
 1069
 1070
 1071
 1072
 1073
 1074
 1075
 1076
 1077
 1078
 1079
 1080
 1081
 1082
 1083
 1084
 1085
 1086
 1087
 1088
 1089
 1090
 1091
 1092
 1093
 1094
 1095
 1096
 1097
 1098
 1099
 1100
 1101
 1102
 1103
 1104
 1105
 1106
 1107
 1108
 1109
 1110
 1111
 1112
 1113
 1114
 1115
 1116
 1117
 1118
 1119
 1120
 1121
 1122
 1123
 1124
 1125
 1126
 1127
 1128
 1129
 1130
 1131
 1132
 1133
 1134
 1135
 1136
 1137
 1138
 1139
 1140
 1141
 1142
 1143
 1144
 1145
 1146
 1147
 1148
 1149
 1150
 1151
 1152
 1153
 1154
 1155
 1156
 1157
 1158
 1159
 1160
 1161
 1162
 1163
 1164
 1165
 1166
 1167
 1168
 1169
 1170
 1171
 1172
 1173
 1174
 1175
 1176
 1177
 1178
 1179
 1180
 1181
 1182
 1183
 1184
 1185
 1186
 1187
 1188
 1189
 1190
 1191
 1192
 1193
 1194
 1195
 1196
 1197
 1198
 1199
 1200
 1201
 1202
 1203
 1204
 1205
 1206
 1207
 1208
 1209
 1210
 1211
 1212
 1213
 1214
 1215
 1216
 1217
 1218
 1219
 1220
 1221
 1222
 1223
 1224
 1225
 1226
 1227
 1228
 1229
 1230
 1231
 1232
 1233
 1234
 1235
 1236
 1237
 1238
 1239
 1240
 1241
 1242
 1243
 1244
 1245
 1246
 1247
 1248
 1249
 1250
 1251
 1252
 1253
 1254
 1255
 1256
 1257
 1258
 1259
 1260
 1261
 1262
 1263
 1264
 1265
 1266
 1267
 1268
 1269
 1270
 1271
 1272
 1273
 1274
 1275
 1276
 1277
 1278
 1279
 1280
 1281
 1282
 1283
 1284
 1285
 1286
 1287
 1288
 1289
 1290
 1291
 1292
 1293
 1294
 1295
 1296
 1297
 1298
 1299
 1300
 1301
 1302
 1303
 1304
 1305
 1306
 1307
 1308
 1309
 1310
 1311
 1312
 1313
 1314
 1315
 1316
 1317
 1318
 1319
 1320
 1321
 1322
 1323
 1324
 1325
 1326
 1327
 1328
 1329
 1330
 1331
 1332
 1333
 1334
 1335
 1336
 1337
 1338
 1339
 1340
 1341
 1342
 1343
 1344
 1345
 1346
 1347
 1348
 1349
 1350
 1351
 1352
 1353
 1354
 1355
 1356
 1357
 1358
 1359
 1360
 1361
 1362
 1363
 1364
 1365
 1366
 1367
 1368
 1369
 1370
 1371
 1372
 1373
 1374
 1375
 1376
 1377
 1378
 1379
 1380
 1381
 1382
 1383
 1384
 1385
 1386
 1387
 1388
 1389
 1390
 1391
 1392
 1393
 1394
 1395
 1396
 1397
 1398
 1399
 1400
 1401
 1402
 1403
 1404
 1405
 1406
 1407
 1408
 1409
 1410
 1411
 1412
 1413
 1414
 1415
 1416
 1417
 1418
 1419
 1420
 1421
 1422
 1423
 1424
 1425
 1426
 1427
 1428
 1429
 1430
 1431
 1432
 1433
 1434
 1435
 1436
 1437
 1438
 1439
 1440
 1441
 1442
 1443
 1444
 1445
 1446
 1447
 1448
 1449
 1450
 1451
 1452
 1453
 1454
 1455
 1456
 1457
 1458
 1459
 1460
 1461
 1462
 1463
 1464
 1465
 1466
 1467
 1468
 1469
 1470
 1471
 1472
 1473
 1474
 1475
 1476
 1477
 1478
 1479
 1480
 1481
 1482
 1483
 1484
 1485
 1486
 1487

(SEQ. ID. NO.)	Xaa ₁	Xaa ₂	Xaa ₃	Xaa ₄	Xaa ₅	Xaa ₆	Xaa ₇	Xaa ₈	Xaa ₉	Xaa ₁₀	Xaa ₁₁	Xaa ₁₂	Xaa ₁₃	Xaa ₁₄	Xaa ₁₅	Xaa ₁₆	Xaa ₁₇	Xaa ₁₈	Xaa ₁₉	2
23	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	pGly	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
24	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	naph	Ile	Glu	Trp	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
25	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Val	Glu	Trp	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
26	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Val	Glu	Phe	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
27	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	tBuG	Glu	Trp	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
28	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	tBuG	Glu	Phe	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
29	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Asp	Trp	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
30	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Phe	Pro	Pro	Pro	Ser	Pro	Ser	NH ₂
31	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	tPro	tPro	tPro	Ser	tPro	Ser	NH ₂
32	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	tPro	tPro	Ser	tPro	Ser	NH ₂
33	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	hPro	hPro	hPro	Ser	hPro	Ser	NH ₂
34	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	hPro	hPro	Ser	hPro	Ser	NH ₂
35	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	tPro	tPro	tPro	Ser	tPro	Ser	NH ₂
36	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	hPro	hPro	hPro	Ser	hPro	Ser	NH ₂
37	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	MeAla	MeAla	MeAla	Ser	MeAla	Ser	NH ₂
38	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Met	Phe	Ile	Glu	Trp	Pro	MeAla	MeAla	Ser	MeAla	Ser	NH ₂
39	His	Gly	Glu	Phe	Thr	Ser	Asp	Leu	Leu	Phe	Ile	Glu	Phe	MeAla	MeAla	MeAla	Ser	MeAla	Ser	NH ₂

FIGURE 10
(Sheet 2 of 2)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)